### PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT8202114

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

### **CONVEYING PARTY DATA**

Name	Execution Date
INTARCIA THERAPEUTICS INC.	12/08/2022

### **RECEIVING PARTY DATA**

Name:	INTARCIA (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
Street Address:	3945 FREEDOM CIRCLE, SUITE #560
City:	SANTA CLARA
State/Country:	CALIFORNIA
Postal Code:	95054

### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	17538507

### **CORRESPONDENCE DATA**

Fax Number: (857)300-4001

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 857-300-4003

Email: bostonpatent@lathropgage.com,dvincent@lathropgage.com,

patricia.ford@lathropgpm.com

**Correspondent Name: BRIAN C. TRINQUE** Address Line 1: LATHROP GPM LLP Address Line 2: 28 STATE STREET

Address Line 4: BOSTON, MASSACHUSETTS 02109

ATTORNEY DOCKET NUMBER:	720191: IOT-048CON2
NAME OF SUBMITTER:	BRIAN C. TRINQUE
SIGNATURE:	/BRIAN C. TRINQUE/
DATE SIGNED:	10/03/2023

### **Total Attachments: 56**

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page1.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w

Exhibits-10-3-2023#page2.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w

Exhibits-10-3-2023#page3.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page4.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page5.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page6.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page7.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page8.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page9.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page10.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page11.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page12.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page13.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page14.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page15.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page16.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page17.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page18.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page19.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page20.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page21.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page22.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page23.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page24.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page25.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page26.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page27.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page28.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page29.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page30.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page31.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page32.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page33.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page34.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page35.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page36.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page37.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page38.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page39.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page40.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page41.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page42.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page43.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page44.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page45.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page46.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page47.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page48.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page49.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page50.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page51.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page52.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page53.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page54.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w Exhibits-10-3-2023#page55.tif

source=720191-2nd-ASSIGNMENT Intarcia THERAPEUTICS TO INTARCIA LLC - Confirmatory Assignment w

PATENT

Exhibits-10-3-2023#page56.tif

## CONFIRMATORY PATENT ASSIGNMENT

WHEREAS by unanimous written consent of the board of directors of Intarcia Therapeutics, Inc., a Delaware corporation ("Intarcia Therapeutics" or the "Company"), and with the consent of the shareholders of the Company, on December 23, 2020, Intarcia Therapeutics, in accordance with the assignment for the benefit of creditors laws of the State of California, did transfer ownership of all of its right, title, and interest in and to all of its assets to Intarcia (assignment for the benefit of creditors), LLC, a California limited liability company (the "Assignee"), and in so doing also designated Assignee to act as the assignee for the benefit of creditors of Intarcia Therapeutics (the "General Assignment" included herewith as Exhibit A);

WHEREAS, pursuant to the terms of the General Assignment between Intarcia Therapeutics and the Assignee, all of the Company's rights, title, and interest in its assets were assigned to the Assignee, including the Company's patents and patent applications;

WHEREAS, in order to memorialize the transfer of the Company's patents and patent applications and related rights to the Assignee, Intarcia Therapeutics did also execute a Patent Assignment Agreement dated December 23, 2020 (the "Patent Assignment Agreement");

WHEREAS, the whereabouts of the Patent Assignment Agreement are unknown; a photograph of the Patent Assignment Agreement is included herewith as Exhibit B;

WHEREAS, the Company and the Assignee wish to memorialize and confirm the transfer of the Company's patents and patent applications and related rights to the Assignee as of December 23, 2020, as expressed in both the General Assignment and the Patent Assignment Agreement;

NOW THEREFORE, Intarcia Therapeutics hereby makes the following Confirmatory Patent Assignment effective *nunc pro tunc* as of December 23, 2020: pursuant to the General Assignment, Intarcia Therapeutics has conveyed, assigned, transferred, delivered and set over for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and does hereby convey, assign, transfer, deliver, and set over, unto said Assignee, its successors and assigns, (1) the entire worldwide right, title, and interest in and to each and all Letters Patents in the United States and in all foreign countries including, without limitation corresponding Patent Cooperation Treaty patent applications and corresponding National patent applications and all inventions, improvements, and discoveries disclosed in said Letters Patents and applications which were held by the Company immediately prior to the consummation of the General Assignment, including those set

forth in Schedule A-1 hereto, and in and to all substitutions, divisions, continuations, continuations-in-part, reexaminations, extensions, renewals, and reissues (as applicable) thereof, including without limitation of generality, all rights of priority resulting from the filing of patent applications relating to any of the foregoing as well as any and all choices in action and any and all claims and demands, both at law and in equity, that Assignor has or may have for damages or profits accrued or to accrue on account of the infringement of any of said Letters Patents, patent applications, inventions, improvements and discoveries (or any provisional rights therein), the same to be held and enjoyed by Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by the Company if the assignment set forth in this Patent Assignment had not been made; (2) the full and complete right to file patent applications in the name of the Company or its designee, at the Assignee's, or its designee's election, on the aforesaid inventions, improvements, discoveries and applications in all countries of the world; and (3) the entire right, title and interest in and to any Letter Patent which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations, and extensions thereof, and any patents of confirmation, registration and importation of the same.

[Remainder of Page Intentionally Left Blank]

2

IN WITNESS THEREOF, Intarcia Therapeutics has caused this Patent Assignment to be signed by its duly authorized officer, *nunc pro tunc* as of December 23, 2020, on this \_\_8th\_ day of \_December\_\_, 2022.

Intarcia Therapeutics, Inc.
<sub>Ву:</sub>
Name: Michael Maidy
Title: Legal Representative
Intarcia (assignment for the benefit of creditors)
LLC, in its sole and limited capacity as the
assignee for the benefit of creditors of Intarcia
Therapeutics, Inc.
Λ .
By: V
Name: Michael Maidy
Title: Manager

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.
STATE OF California  On Provided Company Public, personally appeared  who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.
Cartify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.  WITNESS my hand and official seal.  Signature  CARISSA ANNE KOZACEK Notary Public - California Santa Clara County Commission # 2292012 My Comm. Expires Jun 8, 2023
This area for official notarial seal.
OPTIONAL SECTION - NOT PART OF NOTARY ACKNOWLEDGEMENT CAPACITY CLAIMED BY SIGNER  Though statute does not require the Notary to fill in the data below, doing so may prove invaluable to persons relying on the documents.  INDIVIDUAL CORPORATE OFFICER(S) TITLE(S) PARTNER(S) LIMITED GENERAL ATTORNEY-IN-FACT TRUSTEE(S) GUARDIAN/CONSERVATOR OTHER SIGNER IS REPRESENTING:
Name of Person or Entity  Name of Person or Entity
OPTIONAL SECTION - NOT PART OF NOTARY ACKNOWLEDGEMENT Though the data requested here is not required by law, it could prevent fraudulent reattachment of this form.
THIS CERTIFICATE MUST BE ATTACHED TO THE DOCUMENT DESCRIBED BELOW
TITLE OR TYPE OF DOCUMENT:
NUMBER OF PAGES DATE OF DOCUMENT
SIGNER(S) OTHER THAN NAMED ABOVE Reproduced by First American Title Company 11/2007

CALIFORNIA ALL-PURPOSE ACKNOWLEDGEMENT

## **PATENTS**

# Schedule A-1

605060	605049	605719	605731	605038	605178	605107	606548	606583	606450	717119	724937	616778	606529	606607	Matter No
102487- 039WOAUDIV	102487-039WOAU	102487- 038WOAUDIV	102487-038WOAU	102487-036WOAU	102487-035WOAU	102487-034WOAU	102487-028WOAU	102487-021WOAU	102487-020WOAU	102487-058AR	102487-056AR	102487-055AR	102487-021AR	102487-039EPAL	IP Ref No
ITCA- 039/D01AU	ITCA- 039/N01AU	ITCA- 038/D01AU	ITCA- 038/N01AU	ITCA- 036/N01AU	ITCA- 035/N01AU	ITCA- 034/N01AU	ITCA- 028/N01AU	ITCA- 021/N01AU	ITCA- 020/N01AU		ITCA- 056/N01AR	ITCA- 055/N01AR	ITCA- 021/N01AR	ITCA-039/N01AL	Client Ref No
Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Highly Concentrated Drug Particles, Formulations, Suspensions And Uses Thereof	Highly Concentrated Drug Particles, Formulations, Suspensions And Uses Thereof	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Composition And Dosage Form Comprising An Amphiphilic Molecule As A Suspension Vehicle	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Osmotic Delivery System With Early Zero Order Push Power Engine Comprising An Osmotic Agent Dispersed In The Fluid Vehicle	Long Acting Peptide Tyrosine Tyrosine (PYY) Analogs And Methods Of Use	Long Acting Glucagon Like Polypeptide-1 (GLP-1) Receptor Agonists And Methods Of Use	Human Amylin Analog Polypeptides And Methods Of Use	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Title/Mark
Australia	Australia	Australia	Australia	Australia	Australia	Australia	Australia	Australia	Australia	Argentina	Argentina	Argentina	Argentina	Albania	Country
2014224102	2010298733	2014268265	2009303905	2008244523	2007284759	2007266475	2004291162	2003256308	2003251535	20210101022	20210103539	20190102894	20030102279	10819152.9	Application No
09/21/2010	09/21/2010	10/14/2009	10/14/2009	04/22/2008	08/08/2007	05/30/2007	11/16/2004	06/25/2003	06/17/2003	04/16/2021	12/16/2021	10/11/2019	06/25/2003	09/21/2010	Application Date
09/12/2014	03/09/2012	11/28/2014	04/06/2011	10/15/2009	01/30/2009	10/14/2008	06/02/2005	12/24/2004	12/31/2003					03/06/2012	National Filing Date
2014224102	2010298733	2014268265	2009303905	2008244523	2007284759	2007266475	2004291162	2003256308	2003251535				AR039745B1	2462246	Patent No
08/25/2016	01/22/2015	02/16/2017	05/07/2015	05/31/2012	02/10/2011	03/18/2010	11/12/2009	10/16/2008	04/02/2009	01/01/1900	01/01/1900		06/14/2010	09/06/2017	Grant Date
2014224102		2014268265	2009303905	2008244523	2007284759	2007266475	2004291162	2003256308	2003251535	P210101022		AR116632 A1	AR039745A1	2462246	Publication No
10/02/2014		12/18/2014	04/22/2010	11/06/2008	02/21/2008	12/06/2007	06/02/2005	01/19/2004	12/31/2003	07/20/2022	01/01/1900	05/26/2021	03/09/2005	06/13/2012	Publication Date
Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Published	Pending	Published	Issued	Issued	Status

PATENT

605177	605110	606611	606558	605594	716905	606004	605094	606600	606690	606609	606557	606489	606449	606608	606556	606483	606445	716915	613849	Matter No
102/87-035WOCA	102487-034WOCA	102487-039EPBG	102487-036EPBG	102487- 035WOBGDIV	102487-055BR	102487-048WOBR	102487-043WOBR	102487-043EPBR1	102487-043DEPBR1	102487-039EPBE	102487-036EPBE	102487- 035WOEPBE	102487-035EPBE	102487-039EPAT	102487-036EPAT	102487- 035WOEPAT	102487-035EPAT	102487-055AU	102487-052AU	IP Ref No
ITC A_035 /NI01C A	ITCA-034/N01CA	ITCA- 039/N01BG	ITCA- 036/N01BG	ITCA- 035/D01BG		ITCA-048/N01BR	ITCA-043/N01BR	ITCA-043/02BR1	ITCA-043/03BR1	ITCA-039/N01BE	ITCA-036/N01BE	ITCA-035/N01BE	ITCA-035/D01BE	ITCA-039/N01AT	ITCA-036/N01AT	ITCA-035/N01AT	ITCA-035/D01AT		ITCA- 052/N01AU	Client Ref No
Osmotic Delivery Systems And Piston	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic delivery systems and piston assemblies	Human Amylin Analog Polypeptides And Methods Of Use	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Implant Placement And Removal Systems	Implant Placement Guide	Implant Removal Tool	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Human Amylin Analog Polypeptides And Methods Of Use	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist and Co-Administration of a Drug	Title/Mark
Capada	Canada	Bulgaria	Bulgaria	Bulgaria	Brazil	Brazil	Brazil	Brazil	Brazil	Belgium	Belgium	Belgium	Belgium	Austria	Austria	Austria	Austria	Australia	Australia	Country
2670821	2651855	10819152.9	08743213.4	11165432.3	BR112021006823-6	BR112018073511-6	BR112017025818-8	BR302016005550-5	BR302016005583-1	10819152.9	08743213.4	07811174.7	11165432.3	10819152.9	08743213.4	07811174.7	11165432.3	2019357621	2018206539	Application No
08/08/2007	05/30/2007	09/21/2010	04/22/2008	08/08/2007	10/10/2019	05/15/2017	06/02/2016	11/30/2016	12/01/2016	09/21/2010	04/22/2008	08/08/2007	08/08/2007	09/21/2010	04/22/2008	08/08/2007	08/08/2007	10/10/2019	01/03/2018	Application Date
0.0 / 20009	11/07/2008	03/06/2012	10/12/2009	05/10/2011	04/09/2021	11/14/2018	11/30/2017			03/06/2012	10/12/2009	01/22/2009	05/10/2011	03/06/2012	10/12/2009	01/22/2009	05/10/2011	04/28/2021	07/03/2019	National Filing Date
2670821	2651855	2462246	2157967	EP2359808				BR302016005550-5	BR302016005583-1	2462246	2157967	2049081	2359808	2462246	2157967	2049081	2359808			Patent No
05/15/2012	08/02/2011	09/06/2017	01/16/2013	05/22/2013		01/01/1900	01/01/1900	04/24/2018		09/06/2017	01/16/2013	11/14/2012	05/22/2013	09/06/2017	01/16/2013	11/14/2012	05/22/2013			Grant Date
		2462246		EP2359808		BR112018073511-6	112017025818			2462246			2359808	2462246			2359808	2019357621	2018206539	Publication No
01/01/1900	01/01/1900	06/13/2012	01/01/1900	08/24/2011	07/27/2021	03/26/2019	08/14/2018			06/13/2012	01/01/1900	01/01/1900	08/24/2011	06/13/2012	01/01/1900	01/01/1900	08/24/2011	05/27/2021	07/18/2019	Publication Date
5000	Issued	Issued	Issued	Issued	Pending	Published	Published	Issued	Pending	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Pending	Pending	Status

605047	605720	605597	605192	605114	716906	613840	615035	606003	605095	606613	606602	606601	606697	606696	606689	605048	605714	605036	Matter No
102487-039WOCN	102487-038WOCN	102487- 035WOCNDIV	102487-035WOCN	102487-034WOCN	102487-055CA	102487-052CA	102487-051CA	102487-048WOCA	102487-043WOCA	102487-043EPCA3	102487-043EPCA2	102487-043EPCA1	102487-043DEPCA3	102487-043DEPCA2	102487-043DEPCA1	102487-039WOCA	102487-038WOCA	102487-036WOCA	IP Ref No
039/N01CN	ITCA- 038/N01CN	ITCA- 035/D01CN	ITCA- 035/N01CN	ITCA- 034/N01CN		ITCA-052/N01CA	ITCA-051/N01CA	ITCA-048/N01CA	ITCA-043/N01CA	ITCA-043/02CA3	ITCA-043/02CA2	ITCA-043/02CA1	ITCA-043/03CA3	ITCA-043/03CA2	ITCA-043/03CA1	ITCA-039/N01CA	ITCA-038/N01CA	ITCA-036/N01CA	Client Ref No
Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Highly Concentrated Drug Particles, Formulations, Suspensions And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Human Amylin Analog Polypeptides And Methods Of Use	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist and Co-Administration of a Drug	Apparatus And Methods For Administration Of A Nauseogenic Compound From A Drug Delivery Device	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Implant Placement And Removal Systems	Implant Placement Guide	Implant Placement Guide	Implant Placement Guide	Implant Removal Tool	Implant Removal Tool	Implant Removal Tool	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Highly Concentrated Drug Particles, Formulations, Suspensions And Uses Thereof	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Title/Mark
China	China	China	China	China	Canada	Canada	Canada	Canada	Canada	Canada	Canada	Canada	Canada	Canada	Canada	Canada	Canada	Canada	Country
201080042868.8	200980140859.X	201110114537.7	200780028743.8	200780018756.7	3,116,023	3049034	3,055,759	3024479	2987766	174919	174920	171690	175048	175047	171754	2775676	2738715	2683610	Application No
09/21/2010	10/14/2009	05/05/2011	08/08/2007	05/30/2007	10/10/2019	01/03/2018	03/08/2018	05/15/2017	06/02/2016	11/18/2016	11/18/2016	11/18/2016	11/23/2016	11/23/2016	11/23/2016	09/21/2010	10/14/2009	04/22/2008	Application Date
03/27/2012	04/15/2011	02/01/2009	08/08/2007	11/21/2008	04/07/2021	06/28/2019	09/06/2019	11/15/2018	11/29/2017							03/27/2012	03/28/2011	10/09/2009	National Filing Date
ZL201080042868.8	ZL200980140859.X	ZL201110114537.7	ZL200780028743.8							174919	174920	171690	175048	175047	171754	2775676	2738715	2683610	Patent No
01/19/2018	04/05/2017	12/03/2014	11/09/2011		01/01/1900	01/01/1900	01/01/1900	01/01/1900	01/01/1900	07/28/2017	07/28/2017	07/28/2017	07/31/2017	07/31/2017	07/31/2017	08/16/2016	07/16/2013	01/08/2013	Grant Date
CN102686741A	CN102281865A	CN102274557A	CN101495094	CN101453982															Publication No
09/19/2012	12/14/2011	12/14/2011	07/29/2009	06/10/2009	01/01/1900	01/01/1900	01/01/1900	01/01/1900	01/01/1900	01/01/1900	01/01/1900	01/01/1900	01/01/1900	01/01/1900	01/01/1900		01/01/1900	01/01/1900	Publication Date
Issued	Issued	Issued	Issued	Published	Pending	Pending	Pending	Pending	Pending	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Status

606562	606562	606562	000	606451	606616	606561	606494	606621	606569	716907	613853	615036	606000	720628	605097	606612	606700	605073	605070	Matter No
	102487-034EPDK	102487-039EPCZ	102487-036EPCZ	102487-035EPCZ	102487-039EPCY	102487-036EPCY	102487-035EPCY	102487-039EPHR	102487-036EPHR	102487-055CN	102487-052CN	102487-051CN	102487-048WOCN	102487- 043WOCNDIV	102487-043WOCN	102487-043EPCN1	102487-043DEPCN1	102487- 039WOCNDIV2	102487- 039WOCNDIV	IP Ref No
	ITCA- 034/N01DK	ITCA-039/N01CZ	ITCA-036/N01CZ	ITCA-035/D01CZ	ITCA-039/N01CY	ITCA-036/N01CY	ITCA-035/D01CY	ITCA- 039/N01HR	ITCA- 036/N01HR		ITCA- 052/N01CN	ITCA- 051/N01CN	ITCA- 048/N01CN	ITCA- 043/D01CN	ITCA- 043/N01CN	ITCA-043/02CN1	ITCA-043/03CN1	ITCA- 039/D02CN	ITCA- 039/D01CN	Client Ref No
Osmotic Delivery Systems And Piston	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Human Amylin Analog Polypeptides And Methods Of Use	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist and Co-Administration of a Drug	Apparatus And Methods For Administration Of A Nauseogenic Compound From A Drug Delivery Device	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Implant Placement And Removal Systems	Implant Placement And Removal Systems	Implant Placement Guide	Implant Placement Guide	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Title/Mark
-	Denmark	Czechia	Czechia	Czechia	Cyprus	Cyprus	Cyprus	Croatia	Croatia	China	China	China	China	China	China	China	China	China	China	Country
11165432.3	07797884.9	10819152.9	08743213.4	11165432.3	10819152.9	08743213.4	11165432.3	10819152.9	08743213.4	201980081630.7	201880005825.9	201880026107.X	201780038005.5	202110914048.3	201680044805.3	201630588762.8	201630588754.3	201710980889.8	201410482045.7	Application No
08/08/2007	05/30/2007	09/21/2010	04/22/2008	08/08/2007	09/21/2010	04/22/2008	08/08/2007	09/21/2010	04/22/2008	10/10/2019	01/03/2018	03/08/2018	05/15/2017	06/02/2016	06/02/2016	12/02/2016	12/02/2016	09/21/2010	09/21/2010	Application Date
05/10/2011	11/12/2008	03/06/2012	10/12/2009	05/10/2011	03/06/2012	10/12/2009	05/10/2011	03/06/2012	10/12/2009	06/09/2021	07/03/2019	10/18/2019	12/18/2018	08/10/2021	01/30/2018			09/21/2010	09/19/2014	National Filing Date
2359808	2020990	2462246	2157967	2359808	2462246	2157967	2359808	2462246	2157967						ZL 201680044805.3	ZL 201630588762.8	ZL201630588754.3		ZL 201410482045.7	Patent No
05/22/2013	09/22/2010	09/06/2017	01/16/2013	05/22/2013	09/06/2017	01/16/2013	05/22/2013	09/06/2017	01/16/2013				01/01/1900	01/01/1900	08/27/2021	06/13/2017	06/13/2017	01/01/1900	03/12/2019	Grant Date
7350808		2462246	2157967	2359808	2462246		2359808	2462246		113195524A	110225762A	110545838A	CN 109310743 A	113598842A	107920884A			CN107638562A	CN104323981A	Publication No
08/24/2011	01/01/1900	06/13/2012	03/03/2010	08/24/2011	06/13/2012	01/01/1900	08/24/2011	06/13/2012	01/01/1900	07/30/2021	09/10/2019	12/06/2019	02/05/2019	11/05/2021	04/17/2018			01/30/2018	02/04/2015	Publication Date
Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Published	Published	Published	Published	Published	Issued	Issued	Issued	Published	Issued	Status

605098	707252	605046	606120	605022	605121	606073	606075	606264	606624	606565	606457	606623	606593	606564	606492	Matter No
102487-043WOEP	102487- 039WOEPDV2	102487-039WOEP	102487-037WOEP	102487-036WOEP	102487-034WOEP	102487-021WOEP	102487-020WOEP	102487-017WOEP	102487-039EPEE	102487-036EPEE	102487-035EPEE	102487-039EPDK	102487-037EPDK	102487-036EPDK	102487- 035WOEPDK	IP Ref No
ITCA-043/N01EP		ITCA-039/N01EP	ITCA-037/N01EP	ITCA-036/N01EP	ITCA-034/N01EP	ITCA-021/N01EP	ITCA-020/N01EP	ITCA-017/N01EP	ITCA-039/N01EE	ITCA-036/N01EE	ITCA-035/D01EE	ITCA- 039/N01DK	ITCA- 037/N01DK	ITCA- 036/N01DK	ITCA- 035/N01DK	Client Ref No
Implant Placement And Removal Systems	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Order Push Power Engine Comprising An Order Push Power Engine Comprising An Osmotic Agent Dispersed In The Fluid Vehicle	Osmotic Implant With Membrane And Membrane Retention Means	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Title/Mark
European Patent Office	European Patent Office	European Patent Office	European Patent Office	European Patent Office	European Patent Office	European Patent Office	European Patent Office	European Patent Office	Estonia	Estonia	Estonia	Denmark	Denmark	Denmark	Denmark	Country
16804481.6	20179817.0	10819152.9	09710406.1	08743213.4	07797884.9	03762060.6	03760392.5	02742222.9	10819152.9	08743213.4	11165432.3	10819152.9	09710406.1	08743213.4	07811174.7	Application No
06/02/2016	09/21/2010	09/21/2010	02/12/2009	04/22/2008	05/30/2007	06/25/2003	06/17/2003	06/21/2002	09/21/2010	04/22/2008	08/08/2007	09/21/2010	02/12/2009	04/22/2008	08/08/2007	Application Date
01/03/2018	06/12/2020	03/06/2012	07/29/2010	10/12/2009	11/12/2008	12/23/2004	01/06/2005	01/21/2004	03/06/2012	10/12/2009	05/10/2011	03/06/2012	07/29/2010	10/12/2009	01/22/2009	National Filing Date
		2462246	2240155	2157967	2020990	1551493	1536767	1401395	2462246	2157967	2359808	2462246	2240155	2157967	2049081	Patent No
01/01/1900		09/06/2017	06/06/2012	01/16/2013	09/22/2010	10/31/2007	08/08/2007	04/20/2005	09/06/2017	01/16/2013	05/22/2013	09/06/2017	06/06/2012	01/16/2013	11/14/2012	Grant Date
3302354	3735944	2462246	2240155	2157967	2020990	1551493	1536767	1401395	2462246		2359808	2462246	2240155			Publication No
04/11/2018	11/11/2020	06/13/2012	10/20/2010	03/03/2010	02/11/2009	07/13/2005	06/08/2005	03/31/2004	06/13/2012	01/01/1900	08/24/2011	06/13/2012	10/20/2010	01/01/1900	01/01/1900	Publication Date
Published	Published	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Status

606460	607678	606657	606628	606630	606627	606631	606709	606704	606703	606702	606698	606706	716913	613852	615037	701920	606002	Matter No
102487-035EPFI	102487-043EPEM6	102487-043EPEM5	102487-043EPEM4	102487-043EPEM3	102487-043EPEM2	102487-043EPEM1	102487- 043DEPEM6	102487- 043DEPEM5	102487- 043DEPEM4	102487- 043DEPEM3	102487- 043DEPEM2	102487- 043DEPEM1	102487-055EP	102487-052EP	102487-051EP	102487- 048WOEPDIV	102487-048WOEP	IP Ref No
ITCA-035/D01FI	ITCA- 043/02EM6	ITCA- 043/02EM5	ITCA- 043/02EM4	ITCA- 043/02EM3	ITCA- 043/02EM2			ITCA- 043/03EM5	ITCA- 043/03EM4	ITCA- 043/03EM3	ITCA- 043/03EM2			ITCA-052/N01EP	ITCA-051/N01EP	ITCA-048/D01EP	ITCA-048/N01EP	Client Ref No
Osmotic Delivery Systems And Piston Assemblies	Implant Placement Guide	Implant Removal Tool	Human Amylin Analog Polypeptides And Methods Of Use	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist and Co-Administration of a Drug	Apparatus And Methods For Administration Of A Nauseogenic Compound From A Drug Delivery Device	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Title/Mark										
Finland	European Union	European Union	European Union	European Union	European Union	European Union	European Union	European Patent Office	European Patent Office	European Patent Office	European Patent Office	European Patent Office	Country					
11165432.3	003494970-0006	003494970-0005	003494970-0004	003494970-0003	003494970-0002	003494970-0001	003495787-0006	003495787-0005	003495787-0004	003495787-0003	003495787-0002	003495787-0001	19795724.4	18709116.0	18712409.4	20166273.1	17725143.6	Application No
08/08/2007	12/01/2016	12/01/2016	12/01/2016	12/01/2016	12/01/2016	12/01/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	10/10/2019	01/03/2018	03/08/2018	05/15/2017	05/15/2017	Application Date
05/10/2011													05/07/2021	07/19/2019	09/20/2019	03/27/2020	12/04/2018	National Filing Date
2359808	003494970-0006	003494970-0005	003494970-0004	003494970-0003	003494970-0002	003494970-0001	003495787-0006	003495787-0005	003495787-0004	003495787-0003	003495787-0002	003495787-0001					3458084	Patent No
05/22/2013	12/01/2016	12/01/2016	12/01/2016	12/01/2016	12/01/2016	12/01/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	01/01/1900		01/01/1900	01/01/1900	04/01/2020	Grant Date
2359808													3864031	3565580A0	3592376	3733694	3458084	Publication No
08/24/2011													08/18/2021	11/13/2019	01/15/2020	11/04/2020	03/27/2019	Publication Date
Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Published	Published	Published	Published	Issued	Status

ø
12
2
$\vdash$
0
4

606491	608059	606454	606435	606539	606424	705177	709580	606617	606576	606500	606458	608058	606440	606542	606527	606425	606615	606683	606497	No
102487- 035WOEPDE	102487- 035EPDIV2DE	102487-035EPDE	102487-034EPDE	102487-021EPDE	102487-017EPDE	102487- 048WOEPFR	102487- 039WOEPDIVFR	102487-039EPFR	102487-036EPFR	102487- 035WOEPFR	102487-035EPFR	102487- 035EPDIV2FR	102487-034EPFR	102487-021EPFR	102487-020WOFR	102487-017EPFR	102487-039EPFI	102487-036EPFI	102487-035WOEPFI	IP Ref No
ITCA-035/N01DE	ITCA-035/D02EP	ITCA-035/D01DE	ITCA-034/N01DE	ITCA-021/N01DE	ITCA-017/N01DE		ITCA-039/D01EP	ITCA-039/N01FR	ITCA-036/N01FR	ITCA-035/N01FR	ITCA-035/D01FR	ITCA-035/D02EP	ITCA-034/N01FR	ITCA-021/N01FR	ITCA-020/N01EP	ITCA-017/N01FR	ITCA-039/N01FI	ITCA-036/N01FI	ITCA-035/N01FI	Client Ref No
Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Osmotic Implant With Membrane And Membrane Retention Means	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Osmotic Delivery System With Early Zero Order Push Power Engine Comprising An Osmotic Agent Dispersed In The Fluid Vehicle	Osmotic Implant With Membrane And Membrane Retention Means	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Title/Mark
Germany	Germany	Germany	Germany	Germany	Germany	France	France	France	France	France	France	France	France	France	France	France	Finland	Finland	Finland	Country
07811174.7	11165433.1	11165432.3	07797884.9	03762060.6	02742222.9	17725143.6	17186130.5	10819152.9	08743213.4	07811174.7	11165432.3	11165433.1	07797884.9	03762060.6	03760392.5	02742222.9	10819152.9	08743213.4	07811174.7	Application No
08/08/2007	05/10/2011	05/10/2011	05/30/2007	06/25/2003	06/21/2002	05/15/2017	09/21/2010	09/21/2010	04/22/2008	08/08/2007	08/08/2007	08/08/2007	05/30/2007	06/25/2003	06/17/2003	06/21/2002	09/21/2010	04/22/2008	08/08/2007	Date
01/22/2009	01/22/2009	01/22/2009	11/12/2008	06/25/2003	01/21/2004	12/04/2018	08/14/2017	03/06/2012	10/12/2009	01/22/2009	05/10/2011	01/22/2009	11/12/2008	06/25/2003	01/06/2005	01/21/2004	03/06/2012	10/12/2009	01/22/2009	Filing Date
602007026726.9	602007056486.7	602007030716.3	2020990	60317225.3	1401395	3458084	3323423	2462246	2157967	2049081	2359808	2363112	2020990	1551493	1536767	1401395	2462246	2157967	2049081	Patent No
11/14/2012	10/10/2018	05/22/2013	09/22/2010	10/31/2007	04/20/2005	04/01/2020	06/17/2020	09/06/2017	01/16/2013	11/14/2012	05/22/2013	10/10/2018	09/22/2010	10/31/2007	08/08/2007	04/20/2005	09/06/2017	01/16/2013	11/14/2012	Grant Date
		2359808			1401395			2462246			2359808					1401395	2462246	2157967		Publication No
01/01/1900	01/01/1900	08/24/2011		01/01/1900	03/31/2004	01/01/1900		06/13/2012	01/01/1900	01/01/1900	08/24/2011	01/01/1900		01/01/1900	01/01/1900	03/31/2004	06/13/2012	03/03/2010	01/01/1900	Date
	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Status

606716	606733	605074	605058	605053	606121	605191	605599	605619	605122	606072	606544	606421	606620	606568	606459	705180	709582	606618	606591	606563	Matter No
102487-043DEPHK2	102487-043DEPHK1	102487- 039WOHKDIV2	102487- 039WOHKDIV	102487-039WOHK	102487-037WOHK	102487-035WOHK	102487- 035WOCNDIVHK	102487- 035WOCNDIV2HK	102487- 034WOCNHK	102487- 021WOCNHK	102487-021EPHK	102487-017EPHK	102487-039EPGR	102487-036EPGR	102487-035EPGR	102487- 048WOEPDE	102487- 039WOEPDIVDE	102487-039EPDE	102487-037EPDE	102487-036EPDE	IP Ref No
		ITCA-039/D02HK	ITCA-039/D01HK	ITCA- 039/N01HK	ITCA- 037/N01HK	ITCA- 035/N01HK	ITCA-035/D01HK	ITCA-035/D01HK	ITCA- 034/N01HK	ITCA- 021/N01HK	ITCA- 021/N01HK	ITCA- 017/N01HK	ITCA- 039/N01GR	ITCA- 036/N01GR	ITCA- 035/D01GR		ITCA-039/D01EP	ITCA-039/N01DE	ITCA-037/N01DE	ITCA-036/N01DE	Client Ref No
Implant Removal Tool	Implant Removal Tool	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Osmotic Implant With Membrane And Membrane Retention Means	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Title/Mark
Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Greece	Greece	Greece	Germany	Germany	Germany	Germany	Germany	Country
1602288.9M002	1602288.9M001	18104982.2	15102454.8	12113467.3	11100015.8	09108833.5	11110897.0	11110823.9	09107318.1	06100435.7	06100435.7	05103614.5	10819152.9	08743213.4	11165432.3	17725143.6	17186130.5	10819152.9	09710406.1	08743213.4	Application No
12/02/2016	12/02/2016	09/21/2010	09/21/2010	09/21/2010	02/12/2009	08/08/2007	08/08/2007	08/08/2007	05/30/2007	06/25/2003	06/25/2003	06/21/2002	09/21/2010	04/22/2008	08/08/2007	05/15/2017	09/21/2010	09/21/2010	02/12/2009	04/22/2008	Application Date
		12/27/2012	03/10/2015	12/27/2012	01/04/2011	09/25/2009	10/13/2011	10/12/2011	10/08/2009	01/11/2006	01/11/2006	04/27/2005	03/06/2012	10/12/2009	05/10/2011	12/04/2018	08/14/2017	03/06/2012	07/29/2010	10/12/2009	National Filing Date
1602288.9M002	1602288.9M001		HK1201756	HK1172657	HK1145803	HK1130680	HK1156522	HK1156511	HK1129203	1080402	1080402	1401395	2462246	2157967	2359808	602017014032.5	602010064696.3	2462246	2240155	2157967	Patent No
06/16/2017	06/16/2017		04/24/2020	01/18/2019	10/12/2012	09/07/2012	02/14/2014	11/22/2019	09/16/2011	05/30/2008	05/30/2008	04/20/2005	09/06/2017	01/16/2013	05/22/2013	04/01/2020	06/17/2020	09/06/2017	06/06/2012	01/16/2013	Grant Date
		1245156A	1201756A	1172657A		HK1130680		HK1156511	HK1129203	1671439		HK1070829	2462246		2359808			2462246	2240155		Publication No
		08/24/2018	09/11/2015	04/26/2013		01/08/2010	01/01/1900	06/15/2012	11/20/2009	09/21/2005		06/30/2005	06/13/2012	01/01/1900	08/24/2011	01/01/1900		06/13/2012	10/20/2010	01/01/1900	Publication Date
Issued	Issued	Published	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Status

Matter No	606711	606705	606708	606736	606666	606664	606663	606662	606669	606661	605628	612475	707576	706315	726168	606461	606502	606570	606622	606495	606572	606682	606531
IP Ref No	102487-043DEPHK3	102487-043DEPHK4	102487-043DEPHK5	102487-043DEPHK6	102487-043EPHK1	102487-043EPHK2	102487-043EPHK3	102487-043EPHK4	102487-043EPHK5	102487-043EPHK6	102487- 043WOCNHK	102487- 048WОЕРНК	102487-051EPHK	102487-052НК	102487-055EPHK	102487-035EPHU	102487- 035WOEPHU	102487-036EPHU	102487-039EPHU	102487-035EPIS	102487-036EPIS	102487-039EPIS	102487-021WOIN
Client Ref No											ITCA- 043/N01HK	ITCA- 048/N01HK	ITCA-051/N01EP	ITCA- 052/N01HK		ITCA- 035/D01HU	ITCA- 035/N01HU	ITCA- 036/N01HU	ITCA- 039/N01HU	ITCA-035/D01IS	ITCA-036/N01IS	ITCA-039/N01IS	ITCA-021/N01IN
Title/Mark	Implant Removal Tool	Implant Removal Tool	Implant Removal Tool	Implant Removal Tool	Implant Placement Guide	Implant Placement And Removal Systems	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Apparatus And Methods For Administration Of A Nauseogenic Compound From A Drug Delivery Device	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist and Co-Administration of a Drug	Human Amylin Analog Polypeptides And Methods Of Use	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Osmotic Delivery Systems And Piston Assemblies	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	An Osmotic Delivery System					
Country	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hong Kong	Hungary	Hungary	Hungary	Hungary	Iceland	lceland	Iceland	India				
Application No	1602288.9M003	1602288.9M004	1602288.9M005	1602288.9M006	1602278.8M001	1602278.8M002	1602278.8M003	1602278.8M004	1602278.8M005	1602278.8M006	18112034.3	19123678.5	62020010372.4	62020007444.6	62022048137.3	11165432.3	07811174.7	08743213.4	10819152.9	11165432.3	08743213.4	10819152.9	91/KOLNP/2005
Application Date	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	06/02/2016	05/15/2017	03/08/2018	01/03/2018	10/10/2019	08/08/2007	08/08/2007	04/22/2008	09/21/2010	08/08/2007	04/22/2008	09/21/2010	06/25/2003
National Filing Date											09/19/2018	05/13/2019	07/02/2020	05/13/2020	02/14/2022	05/10/2011	01/22/2009	10/12/2009	03/06/2012	05/10/2011	10/12/2009	03/06/2012	01/25/2005
Patent No	1602288.9M003	1602288.9M004	1602288.9M005	1602288.9M006	1602278.8M001	1602278.8M002	1602278.8M003	1602278.8M004	1602278.8M005	1602278.8M006	HK1252724	HK40000598				2359808	2049081	2157967	2462246	2359808	2157967	2462246	214647
Grant Date	06/16/2017	06/16/2017	06/16/2017	06/16/2017	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/24/2021	01/22/2021			01/01/1900	05/22/2013	11/14/2012	01/16/2013	09/06/2017	05/22/2013	01/16/2013	09/06/2017	02/13/2008
Publication No											1252724 B	40000598	40021195A	40017858A	40059010	2359808		2157967	2462246	2359808		2462246	91/KOLNP/2005
Publication Date											12/24/2021	02/14/2020	10/30/2020	09/25/2020	04/29/2022	08/24/2011	01/01/1900	03/03/2010	06/13/2012	08/24/2011	01/01/1900	06/13/2012	10/07/2005
Status	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Published	Published	Published	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued

~J
9
12
2
$\vdash$
0
4

606523	606431	606684	606594	606571	606503	606463	606448	606545	606432	716920	606010	605104	606322	606402	606699	616394	605034	605018	605138	605120	Matter No
102487-020IL	102487-017WOIL	102487-039EPIE	102487-037EPIE	102487-036EPIE	102487-035WOEPIE	102487-035EPIE	102487-034EPIE	102487-021EPIE	102487-017EPIE	102487-055IN	102487-048WOIN	102487-043WOIN	102487-043EPIN1	102487-043DEPIN2	102487-043DEPIN1	102487- 039WOINDIV	102487- 036WOINDIV	102487-036WOIN	102487-035WOIN	102487-034WOIN	IP Ref No
ITCA-020/N01IL	ITCA-017/N01IL	ITCA-039/N01IE	ITCA-037/N01IE	ITCA-036/N01IE	ITCA-035/N01IE	ITCA-035/D01IE	ITCA-034/N01IE	ITCA-021/N01IE	ITCA-017/N01IE		ITCA-048/N01IN	ITCA-043/N01IN	ITCA-043/02IN1	ITCA-043/03IN2	ITCA-043/03IN1	ITCA-039/D01IN	ITCA-036/D01IN	ITCA-036/N01IN	ITCA-035/N01IN	ITCA-034/N01IN	Client Ref No
Osmotic Delivery System With Early Zero Order Push Power Engine Comprising An Osmotic Agent Dispersed In The Fluid Vehicle	Osmotic Implant With Membrane And Membrane Retention Means	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Osmotic Implant With Membrane And Membrane Retention Means	Human Amylin Analog Polypeptides And Methods Of Use	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Implant Placement And Removal Systems	Implant Placement Guide	Implant Removal Tool	Implant Removal Tool	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Title/Mark
Israel	Israel	Ireland	Ireland	Ireland	Ireland	Ireland	Ireland	Ireland	Ireland	India	India	India	India	India	India	India	India	India	India	India	Country
165697	159374	10819152.9	09710406.1	08743213.4	07811174.7	11165432.3	07797884.9	03762060.6	02742222.9	202117018135	201817045753	201827000190	288949	288951	288950	201918036009	7043/DELNP/2014	6267/DELNP/2009	70/DELNP/2009	9134/DELNP/2008	Application No
06/17/2003	06/21/2002	09/21/2010	02/12/2009	04/22/2008	08/08/2007	08/08/2007	05/30/2007	06/25/2003	06/21/2002	10/10/2019	05/15/2017	06/02/2016	11/29/2016	11/29/2016	11/29/2016	09/21/2010	04/22/2008	04/22/2008	08/08/2007	05/30/2007	Date
12/09/2004	12/15/2003	03/06/2012	07/29/2010	10/12/2009	01/22/2009	05/10/2011	11/12/2008	12/23/2004	01/21/2004	04/20/2021	12/04/2018	01/02/2018				09/06/2019	09/30/2009	09/30/2009	01/05/2009	10/31/2008	Filing Date
165697	159374	2462246	2240155	2157967	2049081	2359808	2020990	1551493	1401395				288949	288951			334581	270290	299985	299954	Patent No
07/30/2010	08/11/2018	09/06/2017	06/06/2012	01/16/2013	11/14/2012	05/22/2013	09/22/2010	10/31/2007	04/20/2005	01/01/1900	01/01/1900	01/01/1900	05/13/2019	05/13/2019		01/01/1900	03/13/2020	12/09/2015	08/14/2018	08/14/2018	Grant Date
		2462246	2240155			2359808			1401395	202117018135A		201827000190 A							24156		Publication No
01/01/1900		06/13/2012	10/20/2010	01/01/1900	01/01/1900	08/24/2011	01/01/1900	01/01/1900	03/31/2004	01/14/2022	01/01/1900	12/21/2018				11/08/2019	01/01/1900	01/01/1900	05/29/2009	03/27/2009	Date
Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Published	Pending	Published	Issued	Issued	Pending	Published	Issued	Issued	Issued	Issued	Status

	613856 10	615038 10	606001 10	721247 0:	10 611993 03	10 605059 03	605040 10	606605 10	727325 03	714120 03	605030 03	605029 03	605021 10	605188 10	605124 10	606550 10	606549 10	606541 10	Matter No IP
	102487-052IL	102487-051IL	102487-048WOIL	102487- 039WOILDIV3	102487- 039WOILDIV2	102487- 039WOILDIV	102487-039WOIL	102487-037WOIL	102487- 036WOILDIV4	102487- 036WOILDIV3	102487- 036WOILDIV2	102487- 036WOILDIV	102487-036WOIL	102487-035WOIL	102487-034WOIL	102487-028WOIL	102487-024WOIL	102487-021WOIL	IP Ref No
	ITCA-052/N01IL	ITCA-051/N01IL	ITCA-048/N01IL	ITCA-039/D03IL	ITCA-039/D02IL	ITCA-039/D01IL	ITCA-039/N01IL	ITCA-037/N01IL	ITCA-036/D04IL	ITCA-036/D03IL	ITCA-036/D02IL	ITCA-036/D01IL	ITCA-036/N01IL	ITCA-035/N01IL	ITCA-034/N01IL	ITCA-028/N01IL	ITCA-024/N01IL	ITCA-021/N01IL	Client Ref No
Human Amylin Analog Polypeptides And	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist and Co-Administration of a Drug	Apparatus And Methods For Administration Of A Nauseogenic Compound From A Drug Delivery Device	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Suspension Formulations of Insulinotropic Peptides and Uses Thereof	Method of Manufacturing an Osmotic Device	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Pharmaceutical Compositions Comprising A Suspending Vehicle And A Particle Preparation And An Osmotic Drug Delivery Device Thereof	Osmostic Pump With Means For Dissipating Internal Pressure	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Title/Mark
erab.	Israel	Israel	Israel	Israel	Israel	Israel	Israel	Israel	Israel	Israel	Israel	Israel	Israel	Israel	Israel	Israel	Israel	Israel	Country
282079	267736	269001	262802	286217	266254	253982	218648	206932	290847	280217	250929	235813	201175	196141	194746	175606	170805	165975	Application No
10/10/2019	01/03/2018	03/08/2018	05/15/2017	09/21/2010	09/21/2010	09/21/2010	09/21/2010	02/12/2009	04/22/2008	04/22/2008	04/22/2008	04/22/2008	04/22/2008	08/08/2007	05/30/2007	11/16/2004	03/31/2004	06/25/2003	Application Date
04/05/2021	06/30/2019	08/29/2019	11/06/2018	09/09/2021	04/28/2019	08/14/2017	03/15/2012	07/11/2010	02/23/2022	01/17/2021	03/05/2017	11/20/2014	09/24/2009	12/23/2008	10/22/2008	05/11/2006	09/12/2005	12/23/2004	National Filing Date
					266254	253982	218648	206932			250929	235813	201175	196141		175606	170805	165975	Patent No
01/01/1900		01/01/1900	01/01/1900	01/01/1900	12/31/2021	12/27/2019	02/01/2018	08/29/2014	01/01/1900	07/02/2022	09/01/2021	07/01/2017	03/01/2015	08/31/2013		07/31/2014	05/18/2010	10/21/2009	Grant Date
					266254		218648	2240155			250929	235813							Publication No
01/01/1900		01/01/1900	01/01/1900	01/01/1900	09/30/2021	10/31/2017	05/31/2012	10/20/2010	01/01/1900	01/01/1900	05/31/2021	03/30/2017		05/30/2013					Publication Date
Ponding	Pending	Pending	Pending	Pending	Issued	Issued	Issued	Issued	Pending	Issued	Issued	Issued	Issued	Issued	Pending	Issued	Issued	Issued	Status

714603	616656	605082	605061	605041	605732	720784	605037	605033	605023	605187	605119	606560	606532	606626	606573	606507	606474	606439	606547	Matter No
102487- 039WOJPDIV5	102487- 039WOJPDIV4	102487- 039WOJPDIV2	102487- 039WOJPDIV	102487-039WOJP	102487-038WOJP	102487- 036WOJPDIV5	102487- 036WOJPDIV2	102487- 036WOJPDIV	102487-036WOJP	102487-035WOJP	102487-034WOJP	102487-028WOJP	102487-021WOJP	102487-039EPIT	102487-036EPIT	102487-035WOEPIT	102487-035EPIT	102487-034EPIT	102487-021EPIT	IP Ref No
ITCA-039/D03JP	ITCA-039/D03JP	ITCA-039/D02JP	ITCA-039/D01JP	ITCA-039/N01JP	ITCA-038/N01JP	ITCA-036/D05JP	ITCA-036/D02JP	ITCA-036/D01JP	ITCA-036/N01JP	ITCA-035/N01JP	ITCA-034/N01JP	ITCA-028/N01JP	ITCA-021/N01JP	ITCA-039/N01IT	ITCA-036/N01IT		ITCA-035/D01IT	ITCA-034/N01IT	ITCA-021/N01IT	Client Ref No
Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Highly Concentrated Drug Particles, Formulations, Suspensions And Uses Thereof	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Composition And Dosage Form Comprising An Amphiphilic Molecule As A Suspension Vehicle	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Title/Mark
Japan	Japan	Japan	Japan	Japan	Japan	Japan	Japan	Japan	Japan	Japan	Japan	Japan	Japan	Italy	Italy	Italy	Italy	Italy	Italy	Country
2021-016605	2019-193440	2016-237525	2014-209225	2012-530862	2011-532079	2021-125462	2016-187105	2013-173812	2010-506245	2009-523832	2009-513435	2006-541326	2004-517856	10819152.9	08743213.4	502013902126414	11165432.3	07797884.9	502008901594603	Application No
09/21/2010	09/21/2010	09/21/2010	09/21/2010	09/21/2010	10/14/2009	04/22/2008	04/22/2008	04/22/2008	04/22/2008	08/08/2007	05/30/2007	11/16/2004	06/25/2003	09/21/2010	04/22/2008	08/08/2007	08/08/2007	05/30/2007	06/25/2003	Application Date
02/04/2021	10/24/2019	12/07/2016	10/10/2014	03/26/2012	04/07/2011	07/30/2021	09/26/2016	08/23/2013	10/15/2009	03/10/2009	11/21/2008	05/17/2006	12/27/2004	03/06/2012	10/12/2009	01/22/2009	05/10/2011	11/12/2008	06/25/2003	National Filing Date
	6835933	6517777	6502643	5718925	5643762		6802019	6016733	5351884	5048773	5143131	4824574	4485945	2462246	2157967	2049081	2359808	2020990	1551493	Patent No
01/01/1900	02/08/2021	04/26/2019	03/29/2019	03/27/2015	11/07/2014		11/30/2020	10/07/2016	08/30/2013	10/17/2012	11/30/2012	09/16/2011	04/02/2010	09/06/2017	01/16/2013	11/14/2012	05/22/2013	09/22/2010	10/31/2007	Grant Date
2021-066747	2020-023562	2017-057212	2015024174	2013-505932	2012-505882	2021-178848	2017-048193	2014040420	2010526775	2010-500890	2009-538717	2007527869	2005530588	2462246			2359808			Publication No
04/30/2021	02/13/2020	03/23/2017	02/05/2015	02/21/2013	03/08/2012	11/18/2021	03/09/2017	03/06/2014	08/05/2010	01/14/2010	11/12/2009	10/04/2007	10/13/2005	06/13/2012	01/01/1900	01/01/1900	08/24/2011	01/01/1900	01/01/1900	Publication Date
Published	Issued	Issued	Issued	Issued	Issued	Published	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Status

606575	606498	606473	606685	606574	606465	606673	606577	606482	716914	613843	615039	730043	606018	724855	605105	606647	606659	606665	701071	606737	606701	Matter No
102487-036EPLU	102487- 035WOEPLU	102487-035EPLU	102487-039EPLT	102487-036EPLT	102487-035EPLT	102487-039EPLV	102487-036EPLV	102487-035EPLV	102487-055JP	102487-052JP	102487-051JP	102487- 048WOJPDV	102487-048WOJP	102487- 043WOJPDIV	102487-043WOJP	102487-043EPJP3	102487-043EPJP2	102487-043EPJP1	102487-043DEPJP2	102487-043DEPJP2	102487-043DEPJP1	IP Ref No
ITCA-036/N01LU	ITCA-035/N01LU	ITCA-035/D01LU	ITCA-039/N01LT	ITCA-036/N01LT	ITCA-035/D01LT	ITCA-039/N01LV	ITCA-036/N01LV	ITCA-035/D01LV		ITCA-052/N01JP	ITCA-051/N01JP		ITCA-048/N01JP	ITCA- 043/N01JPDIV	ITCA-043/N01JP	ITCA-043/02JP1	ITCA-043/02JP2					Client Ref No
Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Human Amylin Analog Polypeptides And Methods Of Use	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist and Co-Administration of a Drug	Apparatus And Methods For Administration Of A Nauseogenic Compound From A Drug Delivery Device	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Implant Placement And Removal Systems	Implant Placement And Removal Systems	Implant Placement Guide	Implant Placement Guide	Implant Placement Guide	Implant Removal Tool	Implant Removal Tool	Implant Removal Tool	Title/Mark
Luxembourg	Luxembourg	Luxembourg	Lithuania	Lithuania	Lithuania	Latvia	Latvia	Latvia	Japan	Japan	Japan	Japan	Japan	Japan	Japan	Japan	Japan	Japan	Japan	Japan	Japan	Country
08743213.4	07811174.7	11165432.3	10819152.9	08743213.4	11165432.3	10819152.9	08743213.4	11165432.3	2021-519698	2019-536181	2019-548709	2022-81652	2018-560659	2021-200063	2017-562649	2017-13365	D2017-13356	2016-26233	JP2017-12968	2017-12969	2016-26195	Application No
04/22/2008	08/08/2007	08/08/2007	09/21/2010	04/22/2008	08/08/2007	09/21/2010	04/22/2008	08/08/2007	10/10/2019	01/03/2018	03/08/2018	05/15/2017	05/15/2017	06/02/2016	06/02/2016	12/02/2016	12/02/2016	12/02/2016	01/27/2017	12/02/2016	12/02/2016	Application Date
10/12/2009	01/22/2009	05/10/2011	03/06/2012	10/12/2009	05/10/2011	03/06/2012	10/12/2009	05/10/2011	04/09/2021	07/02/2019	09/06/2019	05/18/2022	11/15/2018	12/09/2021	12/01/2017							National Filing Date
2157967	2049081	2359808	2462246	2157967	2359808	2462246	2157967	2359808					7077237		6993235	1595274	D1595315	D1595274	6453920	1596822	1593290	Patent No
01/16/2013	11/14/2012	05/22/2013	09/06/2017	01/16/2013	05/22/2013	09/06/2017	01/16/2013	05/22/2013	01/01/1900		01/01/1900	01/01/1900	05/20/2022	01/01/1900	12/13/2021	12/22/2017	12/22/2017	12/22/2017	01/08/2019	01/12/2018	11/24/2017	Grant Date
		2359808	2462246		2359808	2462246		2359808	2022-504596		2020-510028		2019520329	2022-031898	2018-525047							Publication No
01/01/1900	01/01/1900	08/24/2011	06/13/2012	01/01/1900	08/24/2011	06/13/2012	01/01/1900	08/24/2011	01/13/2022		04/02/2020	01/01/1900	07/18/2019	02/22/2022	09/06/2018							Publication Date
Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Published	Pending	Published	Pending	Issued	Published	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Status

605103	605650	605652	712872	605064	605045	605730	605025	605185	605117	606526	606426	606433	606671	606579	606480	605044	610549	606672	Matter No
102487-043WOMX	102487- 043DCONMX	102487-043D2MX	102487- 039WOMXDIV2	102487- 039WOMXDIV	102487-039WOMX	102487-038WOMX	102487-036WOMX	102487-035WOMX	102487-034WOMX	102487-020WOMX	102487-019WOMX	102487-017WOMX	102487-039EPMT	102487-036EPMT	102487-035EPMT	102487-039WOMO	102487- 039WOCNDIVMO	102487-039EPLU	IP Ref No
ITCA- 043/N01MX	ITCA- 043/02MX1	ITCA- 043/03MX1		ITCA- 039/D01MX	ITCA- 039/N01MX	ITCA- 038/N01MX	ITCA- 036/N01MX	ITCA- 035/N01MX	ITCA- 034/N01MX	ITCA- 020/N01MX	ITCA- 019/N01MX	ITCA- 017/N01MX	ITCA- 039/N01MT	ITCA- 036/N01MT	ITCA- 035/D01MT	ITCA- 039/N01MO	ITCA- 039/D01CNMO	ITCA-039/N01LU	Client Ref No
Implant Placement And Removal Systems	Implant Removal Tool	Implant Removal Tool	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Highly Concentrated Drug Particles, Formulations, Suspensions And Uses Thereof	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Supply Systems And Piston Assemblies	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Osmotic Delivery System With Early Zero Order Push Power Engine Comprising An Osmotic Agent Dispersed In The Fluid Vehicle	Osmotic Delivery Device Having A Two- Way Valve And A Dynamically Self- Adjusting Flow Channel	Osmotic Implant With Membrane And Membrane Retention Means	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Title/Mark
Mexico	Mexico	Mexico	Mexico	Mexico	Mexico	Mexico	Mexico	Mexico	Mexico	Mexico	Mexico	Mexico	Malta	Malta	Malta	Macao	Macao	Luxembourg	Country
MX/a/2017/015504	MX/f/2016/003825	MX/f/2016/003824	MX/a/2021/000241	MX/a/2017/004990	MX/a/2012/003680	MX/a/2011/003833	Mx/a/2009/011123	MX/a/2009/001114	MX/a/2008/014870	PA/a/2004/012976	PA/a/2004/004881	PA/A/2004/000019	10819152.9	08743213.4	11165432.3	J/003051	J/003679	10819152.9	Application No
06/02/2016	12/01/2016	12/01/2016	09/21/2010	09/21/2010	09/21/2010	10/14/2009	04/22/2008	08/08/2007	05/30/2007	06/17/2003	11/21/2002	06/21/2002	09/21/2010	04/22/2008	08/08/2007	09/21/2010	09/21/2010	09/21/2010	Application Date
11/30/2017	06/02/2016	06/02/2016	01/07/2021	03/27/2012	03/27/2012	04/08/2011	10/15/2009	01/28/2009	11/21/2008	12/17/2004	05/21/2004	01/07/2004	03/06/2012	10/12/2009	05/10/2011	04/19/2018	05/10/2019	03/06/2012	National Filing Date
	54092	54091		378797	352878	335455	315269	282429	285745	256018	258594	247099	2462246	2157967	2359808	J/003051	J/003679	2462246	Patent No
01/01/1900	11/20/2018	11/20/2018		01/08/2021	12/13/2017	12/07/2015	11/12/2013	12/21/2010	04/15/2011	04/04/2008	07/08/2008	07/09/2007	09/06/2017	01/16/2013	05/22/2013	07/20/2018	10/23/2019	09/06/2017	Grant Date
			MX/a/2021/000241				2009011123	2009001114	2008014870	PA04012976	PA04004881	PA04000019	2462246		2359808			2462246	Publication No
01/01/1900	01/01/1900	01/01/1900	05/14/2021		06/05/2012	07/28/2011	11/02/2009	02/10/2009	06/03/2011	05/16/2005	09/03/2004	02/01/2008	06/13/2012	01/01/1900	08/24/2011	08/15/2018	07/17/2019	06/13/2012	Publication Date
Pending	Issued	Issued	Published	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Status

	a.
4	ō.
1	3
ŧ	J
н	_
(	$\overline{}$
á	$\overline{a}$

605026	605598	605181	605115	606536	606679	606595	606582	606508	606479	606443	606546	606681	606578	606501	606481	716989	613842	615042	606012	Matter No
102487-036WONZ	102487- 035WONZDIV	102487-035WONZ	102487-034WONZ	102487-021WONZ	102487-039EPNL	102487-037EPNL	102487-036EPNL	102487- 035WOEPNL	102487-035EPNL	102487-034EPNL	102487-021EPNL	102487-039EPMC	102487-036EPMC	102487- 035WOEPMC	102487-035EPMC	102487-055MX	102487-052MX	102487-051MX	102487-048WOMX	IP Ref No
ITCA-036/N01NZ	ITCA-035/D01NZ	ITCA-035/N01NZ	ITCA-034/N01NZ	ITCA-021/N01NZ	ITCA-039/N01NL	ITCA-037/N01NL	ITCA-036/N01NL	ITCA-035/N01NL	ITCA-035/D01NL	ITCA-034/N01NL	ITCA-021/N01NL	ITCA- 039/N01MC	ITCA- 036/N01MC	ITCA- 035/N01MC	ITCA- 035/D01MC	ITCA- 055/N01MX	ITCA- 052/N01MX	ITCA- 051/N01MX	ITCA- 048/N01MX	Client Ref No
Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator With Spiral Fluid Channel	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Human Amylin Analog Polypeptides And Methods Of Use	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist and Co-Administration of a Drug	Apparatus And Methods For Administration Of A Nauseogenic Compound From A Drug Delivery Device	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Title/Mark
New Zealand	New Zealand	New Zealand	New Zealand	New Zealand	Netherlands	Netherlands	Netherlands	Netherlands	Netherlands	Netherlands	Netherlands	Monaco	Monaco	Monaco	Monaco	Mexico	Mexico	Mexico	Мехісо	Country
580447	593017	574524	572003	537628	10819152.9	09710406.1	08743213.4	07811174.7	11165432.3	07797884.9	03762060.6	10819152.9	08743213.4	07811174.7	11165432.3	MX/a/2021/004185	MX/A/2019/008006	MX/A/2019/010651	MX/A/2018/014016	Application No
04/22/2008	05/23/2011	08/08/2007	05/30/2007	06/25/2003	09/21/2010	02/12/2009	04/22/2008	08/08/2007	08/08/2007	05/30/2007	06/25/2003	09/21/2010	04/22/2008	08/08/2007	08/08/2007	10/10/2019	01/03/2018	03/08/2018	05/15/2017	Application Date
10/15/2009	01/30/2009	01/30/2009	10/15/2008	01/12/2005	03/06/2012	07/29/2010	10/12/2009	01/22/2009	05/10/2011	11/12/2008	06/25/2003	03/06/2012	10/12/2009	01/22/2009	05/10/2011	04/09/2021	07/02/2019	09/06/2019	11/15/2018	National Filing Date
580447	593017	574524	572003	537628	2462246	2240155	2157967	2049081	2359808	2020990	1551493	2462246	2157967	2049081	2359808					Patent No
10/10/2011	12/05/2011	11/07/2011	11/06/2010	04/06/2006	09/06/2017	06/06/2012	01/16/2013	11/14/2012	05/22/2013	09/22/2010	10/31/2007	09/06/2017	01/16/2013	11/14/2012	05/22/2013				01/01/1900	Grant Date
580447		574524	572003	537628	2462246	2240155			2359808		1551493	2462246			2359808	MX/a/2021/004185	MX/A/2019/008006			Publication No
06/30/2011	08/26/2011	07/29/2011	07/30/2010	12/23/2005	06/13/2012	10/20/2010	01/01/1900	01/01/1900	08/24/2011	01/01/1900	07/13/2005	06/13/2012	01/01/1900	01/01/1900	08/24/2011	10/14/2021	09/13/2019	02/12/2020	09/13/2019	Publication Date
Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Published	Published	Published TEN	Published	Status

<b>u</b>	
ø	
12	
2	
$\vdash$	
0	
4	

606677	606585	606680	716923	613844	615043	606015	718997	605102	606660	606658	606648	606645	606641	606638	607075	605067	605065	605052	605729	No
102487-039EPNO	102487-036EPNO	102487-039EPMK	102487-055NZ	102487-052NZ	102487-051NZ	102487-048WONZ	102487- 043WONZDIV	102487-043WONZ	102487-043EPNZ3	102487-043EPNZ2	102487-043EPNZ1	102487-043DEPNZ3	102487-043DEPNZ2	102487-043DEPNZ1	102487- 039WONZDIV4	102487- 039WONZDIV3	102487- 039WONZDIV	102487-039WONZ	102487-038WONZ	IP Ref No
ITCA- 039/N01NO	ITCA- 036/N01NO	ITCA- 039/N01MK		ITCA-052/N01NZ	ITCA-051/N01NZ	ITCA-048/N01NZ	ITCA-043/D01NZ	ITCA-043/N01NZ	ITCA-043/02NZ3	ITCA-043/02NZ2	ITCA-043/02NZ1	ITCA-043/03NZ3	ITCA-043/03NZ2	ITCA-043/03NZ1	ITCA-039/D03NZ	ITCA-039/D03NZ	ITCA-039/D01NZ	ITCA-039/N01NZ	ITCA-038/N01NZ	Client Ref No
Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Human Amylin Analog Polypeptides And Methods Of Use	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist and Co-Administration of a Drug	Apparatus And Methods For Administration Of A Nauseogenic Compound From A Drug Delivery Device	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Implant Placement And Removal Systems	Implant Placement And Removal Systems	Implant Placement Guide	Implant Placement Guide	Implant Placement Guide	Implant Removal Tool	Implant Removal Tool	Implant Removal Tool	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Highly Concentrated Drug Particles, Formulations, Suspensions And Uses Thereof	Title/Mark
Norway	Norway	North Macedonia	New Zealand	New Zealand	New Zealand	New Zealand	New Zealand	New Zealand	New Zealand	New Zealand	New Zealand	New Zealand	New Zealand	New Zealand	New Zealand	New Zealand	New Zealand	New Zealand	New Zealand	Country
10819152.9	08743213.4	10819152.9	775502	755043	756947	748486	776713	738102	423140	423139	422361	423138	423137	422360	747990	731923	624569	598686	592113	Application No
09/21/2010	04/22/2008	09/21/2010	10/10/2019	01/03/2018	03/08/2018	05/15/2017	06/02/2016	06/02/2016	11/23/2016	11/23/2016	11/23/2016	11/23/2016	11/23/2016	11/23/2016	09/21/2010	09/21/2010	09/21/2010	09/21/2010	10/14/2009	Date
03/06/2012	10/12/2009	03/06/2012	04/28/2021	07/02/2019	09/04/2019	11/20/2018	05/31/2021	12/06/2017	06/07/2017	06/07/2017	06/07/2017	06/07/2017			11/02/2018	05/15/2017	05/05/2014	03/09/2012	04/06/2011	Filing Date
2462246	2157967	2462246							423140	423139	422361	423138	423137	422360	747990	731923	624569	598686	592113	Patent No
09/06/2017	01/16/2013	09/06/2017				01/01/1900	01/01/1900		06/15/2017	06/15/2017	06/15/2017	06/09/2017	06/09/2017	06/09/2017	09/29/2020	03/01/2019	05/03/2016	09/02/2014	08/06/2012	Grant Date
2462246		2462246																598686	592113	Publication No
06/13/2012	01/01/1900	06/13/2012				01/01/1900	01/01/1900										01/29/2016	05/30/2014	04/27/2012	Date
Issued	Issued	Issued	Pending	Pending	Pending	Pending	Pending	Pending	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Status

ũ	7
1	۲.
ř	۲.
à	~
2	╗
4	Z

606722	606735	612433	611611	605043	605733	605024	605186	605116	606534	606676	606581	606477	606678	606580	606478	717156	717149	717120	724939	Matter No
102487-043DEPKR2	102487-043DEPKR1	102487- 039WOKRDIV3	102487- 039WOKRDIV2	102487-039WOKR	102487-038WOKR	102487-036WOKR	102487-035WOKR	102487-034WOKR	102487-021WOKR	102487-039EPPT	102487-036EPPT	102487-035EPPT	102487-039EPPL	102487-036EPPL	102487-035EPPL	102487-060WO	102487-059WO	102487-058WO	102487-056WO	IP Ref No
		ITCA-039/D03KR	ITCA-039/D02KR	ITCA-039/N01KR	ITCA-038/N01KR	ITCA-036/N01KR	ITCA-035/N01KR	ITCA-034/N01KR	ITCA-021/N01KR	ITCA-039/N01PT	ITCA-036/N01PT	ITCA-035/D01PT	ITCA-039/N01PL	ITCA-036/N01PL	ITCA-035/D01PL					Client Ref No
Implant Removal Tool	Implant Removal Tool	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Highly Concentrated Drug Particles, Formulations, Suspensions And Uses Thereof	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Use Of Human Amylin Analog Polypeptides For Providing Superior Glycemic Control To Type 1 Diabetics	Long Acting Glucagon Receptor Selective Peptides And Methods Of Use	Long Acting Peptide Tyrosine Tyrosine (PYY) Analogs And Methods Of Use	Long Acting Glucagon Like Polypeptide-1 (GLP-1) Receptor Agonists And Methods Of Use	Title/Mark
Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Portugal	Portugal	Portugal	Poland	Poland	Poland	РСТ	PCT	PCT	РСТ	Country
30-2016- 0058499(M002)	30-2016- 0058499(M001)	10-2019-7023817	10-2019-7003513	10-2012-7007802	10-2011-7008047	10-2009-7021476	10-2009-7002057	10-2008-7028256	10-2004-7021083	10819152.9	08743213.4	11165432.3	10819152.9	08743213.4	11165432.3	PCT/US21/28209	PCT/US21/27763	PCT/US21/27759	PCT/US21/63920	Application No
12/02/2016	12/02/2016	09/21/2010	09/21/2010	09/21/2010	10/14/2009	04/22/2008	08/08/2007	05/30/2007	06/25/2003	09/21/2010	04/22/2008	08/08/2007	09/21/2010	04/22/2008	08/08/2007	04/20/2021	04/16/2021	04/16/2021	12/16/2021	Application Date
		08/13/2019	02/01/2019	03/26/2012	04/07/2011	10/14/2009	01/30/2009	11/19/2008	12/24/2004	03/06/2012	10/12/2009	05/10/2011	03/06/2012	10/12/2009	05/10/2011					National Filing Date
3009263640002	3009263640001	10-2148624	10-2093612	1018236990000	1014195830000	10-1208381	1012007280000	10-1106510	1010469030000	2462246	2157967	2359808	2462246	2157967	2359808					Patent No
10/10/2017	10/10/2017	08/20/2020	03/20/2020	01/24/2018	07/08/2014	11/29/2012	11/07/2012	01/10/2012	06/30/2011	09/06/2017	01/16/2013	05/22/2013	09/06/2017	01/16/2013	05/22/2013				01/01/1900	Grant Date
		20190098274	20190016599	1020120064089	1020110069054	20090122386		1020090003342	1020050026416	2462246		2359808	2462246		2359808	WO 2021/216586	WO 2021/212026	WO 2021/212023	WO 2022/133148	Publication No
		08/21/2019	02/18/2019	06/18/2012	06/22/2011	11/27/2009	11/13/2012	01/09/2009	03/15/2005	06/13/2012	01/01/1900	08/24/2011	06/13/2012	01/01/1900	08/24/2011	10/28/2021	10/21/2021	10/21/2021	06/23/2022	Publication Date
Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Published	Published	Published	Pending	Status

605081	605063	605051	605027	606675	606589	716904	613850	615040	606011	605101	606649	606653	606650	606651	606655	606656	606640	606642	606707	Matter No
102487- 039WORUDIV2	102487- 039WORUDIV	102487-039WORU	102487-036WORU	102487-039EPRO	102487-036EPRO	102487-055KR	102487-052KR	102487-051KR	102487-048WOKR	102487-043WOKR	102487-043EPKR6	102487-043EPKR5	102487-043EPKR4	102487-043EPKR3	102487-043EPKR2	102487-043EPKR1	102487-043DEPKR6	102487-043DEPKR5	102487-043DEPKR3	IP Ref No
ITCA- 039/D02RU	ITCA- 039/D01RU	ITCA- 039/N01RU	ITCA- 036/N01RU	ITCA- 039/N01RO	ITCA- 036/N01RO		ITCA-052/N01KR	ITCA-051/N01KR	ITCA-048/N01KR	ITCA-043/N01KR										Client Ref No
Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Human Amylin Analog Polypeptides And Methods Of Use	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist and Co-Administration of a Drug	Apparatus And Methods For Administration Of A Nauseogenic Compound From A Drug Delivery Device	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Implant Placement And Removal Systems	Implant Placement Guide	Implant Removal Tool	Implant Removal Tool	Implant Removal Tool	Title/Mark					
Russian Federation	Russian Federation	Russian Federation	Russian Federation	Romania	Romania	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Republic of Korea	Country
2015107870	2014136091	2012110926	2009143016	10819152.9	08743213.4	10-2021-7013697	10-2019-7021079	10-2019-7027476	10-2018-7036116	10-2018-7000070	30-2016- 0058498(M006)	30-2016- 0058498(M005)	30-2016- 0058498(M004)	30-2016- 0058498(M003)	30-2016- 0058498(M002)	30-2016- 0058498(M001)	30-2016- 0058499(M006)	30-2016- 0058499(M005)	30-2016- 0058499(M003)	Application No
09/21/2010	09/21/2010	09/21/2010	04/22/2008	09/21/2010	04/22/2008	10/10/2019	01/03/2018	03/08/2018	05/15/2017	06/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	Application Date
03/06/2015	07/01/2014	04/28/2012	11/23/2009	03/06/2012	10/12/2009	05/06/2021	07/18/2019	09/19/2019	12/12/2018	01/02/2018										National Filing Date
2753280	2703471	2547990	2440097	2462246	2157967						3009263340006	3009263340005	3009263340004	3009263340003	3009263340002	3009263340001	3009263640006	3009263640005	3009263640003	Patent No
08/12/2021	10/17/2019	04/10/2015	01/20/2012	09/06/2017	01/16/2013	01/01/1900			01/01/1900	01/01/1900	10/10/2017	10/10/2017	10/10/2017	10/10/2017	10/10/2017	10/10/2017	10/10/2017	10/10/2017	10/10/2017	Grant Date
2015107870	2014136091	2012110926	2009143016	2462246		20210091705		20190126335	10-2019-0008554	20180014814										Publication No
10/27/2015	03/27/2016	11/10/2013	05/27/2011	06/13/2012	01/01/1900	07/22/2021		11/11/2019	01/24/2019	02/09/2018										Publication Date
Issued	Issued	Issued	Issued	Issued	Issued	Published	Pending	Published	Published	Published	Issued	Status								

<b>√</b> 1
ø
12
2
$\vdash$
0
4

102487-043EPZA1	1024		I	606485	606634	606586	606475	716922	724856	605099	606670	606668	606636	606633	716988	723885	606013	605100	606667	606639	720627	Matter No
	102487-043DEPZA1	102487-039EPSI	102487-036EPSI	102487-035EPSI	102487-039EPSK	102487-036EPSK	102487-035EPSK	102487-055SG	102487- 043WOSGDIV	102487-043WOSG	102487-043EPSG2	102487-043EPSG1	102487-043DEPSG1	102487-039EPSM	102487-055RU	102487- 048WORUDIV	102487-048WORU	102487-043WORU	102487-043EPRU1	102487-043DEPRU1	102487- 039WORUDIV3	IP Ref No
ITCA-043/02ZA1	ITCA-043/03ZA1	ITCA-039/N01SI	ITCA-036/N01SI	ITCA-035/D01SI	ITCA-039/N01SK	ITCA-036/N01SK	ITCA-035/D01SK		ITCA-043/D01SG	ITCA-043/N01SG	ITCA-043/02SG2	ITCA-043/02SG1	ITCA-043/03SG1	ITCA- 039/N01SM			ITCA- 048/N01RU	ITCA- 043/N01RU	ITCA-043/02RU1	ITCA-043/03RU1	ITCA- 039/D03RU	Client Ref No
Implant Placement Guide	Implant Placement Guide	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Human Amylin Analog Polypeptides And Methods Of Use	Implant Placement And Removal Systems	Implant Placement And Removal Systems	Implant Placement Guide	Implant Placement Guide	Implant Removal Tool	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Human Amylin Analog Polypeptides And Methods Of Use	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Implant Placement And Removal Systems	Implant Placement Guide	Implant Placement Guide	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Title/Mark
South Africa	South Africa	Slovenia	Slovenia	Slovenia	Slovakia	Slovakia	Slovakia	Singapore	Singapore	Singapore	Singapore	Singapore	Singapore	San Marino	Russian Federation	Russian Federation	Russian Federation	Russian Federation	Russian Federation	Russian Federation	Russian Federation	Country
2016/01755	2016/01754	10819152.9	08743213.4	11165432.3	10819152.9	08743213.4	11165432.3	11202103586U	10202113630U	11201709931R	30201603176W	30201603174V	30201603175Q	10819152.9	2021110342	2021132343	2018139166	2017142338	2016504905	2016504904	2021122069	Application No
11/22/2016	11/22/2016	09/21/2010	04/22/2008	08/08/2007	09/21/2010	04/22/2008	08/08/2007	10/10/2019	06/02/2016	06/02/2016	11/29/2016	11/29/2016	11/29/2016	09/21/2010	10/10/2019	05/15/2017	05/15/2017	06/02/2016	12/01/2016	12/01/2016	09/21/2010	Application Date
		03/06/2012	10/12/2009	05/10/2011	03/06/2012	10/12/2009	05/10/2011	04/08/2021	12/08/2021	11/30/2017				03/06/2012	04/14/2021	11/08/2021	11/07/2018	01/09/2018			07/26/2021	National Filing Date
F2016/01755	F2016/01754	2462246	2157967	2359808	2462246	2157967	2359808			11201709931R	30201603176W	30201603174V		2462246			2760007	2730996	00107640	00107639		Patent No
12/23/2016	06/27/2017	09/06/2017	01/16/2013	05/22/2013	09/06/2017	01/16/2013	05/22/2013			12/31/2021	03/30/2018	03/30/2018		09/06/2017		01/01/1900	11/22/2021	08/26/2020	03/30/2018	03/30/2018		Grant Date
		2462246		2359808	2462246		2359808	11202103586U						2462246			2018139166	2017142338				Publication No
		06/13/2012	01/01/1900	08/24/2011	06/13/2012	01/01/1900	08/24/2011	05/28/2021	01/28/2022					06/13/2012		01/01/1900	06/17/2020	07/10/2019				Publication Date
Issued	Issued	Issued	) Issued	Issued	Issued	lssued	Issued	Published	Published	Issued	Issued	Issued	Pending		Pending	) Pending	) Issued	Ssued	Issued	Issued	Pending	Status

606596	606559	606490	606496	606453	606438	606537	606674	606587	606505	606476	606625	606566	606493	606455	606436	606540	716921	727326	605096	Matter No
102487-037EPCH	102487-036EPCH	102487- 035WOEPCH	102487-035EPRO	102487-035EPCH	102487-034EPCH	102487-021EPCH	102487-039EPSE	102487-036EPSE	102487- 035WOEPSE	102487-035EPSE	102487-039EPES	102487-036EPES	102487- 035WOEPES	102487-035EPES	102487-034EPES	102487-021EPES	102487-055ZA	102487- 043WOZADV	102487-043WOZA	IP Ref No
037/N01CH	ITCA- 036/N01CH	ITCA- 035/N01CH	ITCA- 035/D01HU	ITCA- 035/D01CH	ITCA- 034/N01CH	ITCA- 021/N01CH	ITCA-039/N01SE	ITCA-036/N01SE	ITCA-035/N01SE	ITCA-035/D01SE	ITCA-039/N01ES	ITCA-036/N01ES	ITCA-035/N01ES	ITCA-035/D01ES	ITCA-034/N01ES	ITCA-021/N01ES		ITCA-043/D01ZA	ITCA-043/N01ZA	Client Ref No
Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Two Piece Internal Channel Osmotic Delivery System Flow Modulator	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Human Amylin Analog Polypeptides And Methods Of Use	Implant Placement And Removal Systems	Implant Placement And Removal Systems	Title/Mark
Switzerland	Switzerland	Switzerland	Switzerland	Switzerland	Switzerland	Switzerland	Sweden	Sweden	Sweden	Sweden	Spain	Spain	Spain	Spain	Spain	Spain	South Africa	South Africa	South Africa	Country
09710406.1	08743213.4	07811174.7	11165432.3	11165432.3	07797884.9	03762060.6	10819152.9	08743213.4	07811174.7	11165432.3	10819152.9	08743213.4	07811174.7	11165432.3	07797884.9	03762060.6	2021/02329	2022/02467	2017/08200	Application No
02/12/2009	04/22/2008	08/08/2007	08/08/2007	08/08/2007	05/30/2007	06/25/2003	09/21/2010	04/22/2008	08/08/2007	08/08/2007	09/21/2010	04/22/2008	08/08/2007	08/08/2007	05/30/2007	06/25/2003	10/10/2019	06/02/2016	06/02/2016	Application Date
07/29/2010	10/12/2009	01/22/2009	05/10/2011	05/10/2011	11/12/2008	06/25/2003	03/06/2012	10/12/2009	01/22/2009	05/10/2011	03/06/2012	10/12/2009	01/22/2009	05/10/2011	11/12/2008	06/25/2003	04/08/2021	02/28/2022	12/01/2017	National Filing Date
2240155	2157967	2049081	2359808	2359808	2020990	1551493	2462246	2157967	2049081	2359808	2462246	2157967	2049081	2359808	2020990	ES2295642				Patent No
06/06/2012	01/16/2013	11/14/2012	05/22/2013	05/22/2013	09/22/2010	10/31/2007	09/06/2017	01/16/2013	11/14/2012	05/22/2013	09/06/2017	01/16/2013	11/14/2012	05/22/2013	09/22/2010	10/31/2007		01/01/1900	01/01/1900	Grant Date
2240155			2359808	2359808			2462246	2157967		2359808	2462246			2359808						Publication No
10/20/2010	01/01/1900	01/01/1900	08/24/2011	08/24/2011		01/01/1900	06/13/2012	03/03/2010	01/01/1900	08/24/2011	06/13/2012	01/01/1900	01/01/1900	08/24/2011	01/01/1900	01/01/1900		01/01/1900	01/01/1900	Publication Date
Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Pending	Pending	Allowed	Status

709581	606619	606567	606509	606462	608062	606441	606543	606528	606427	606635	606471	717118	724938	616783	726167	605087	606603	606610	Matter No
102487- 039WOEPDIVGB	102487-039EPGB	102487-036EPGB	102487- 035WOEPGB	102487-035EPGB	102487- 035EPDIV2GB	102487-034EPGB	102487-021EPGB	102487-020WOGB	102487-017EPGB	102487-039EPTR	102487-035EPTR	102487-058TW	102487-056TW	102487-055TW	102487-048TWDV	102487-048TW	102487-043EPCH1	102487-039EPCH	IP Ref No
	ITCA- 039/N01GB	ITCA- 036/N01GB	ITCA- 035/N01GB	ITCA- 035/D01GB	ITCA-035/D02EP	ITCA- 034/N01GB	ITCA- 021/N01GB	ITCA-020/N01EP	ITCA- 017/N01GB	ITCA-039/N01TR	ITCA-035/D01TR		ITCA- 056/N01TW	ITCA- 055/N01TW	ITCA- 048/D01TW	ITCA- 048/N01TW	ITCA-043/02CH1	ITCA- 039/N01CH	Client Ref No
Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Osmotic Delivery System With Early Zero Order Push Power Engine Comprising An Osmotic Agent Dispersed In The Fluid Vehicle	Osmotic Implant With Membrane And Membrane Retention Means	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Osmotic Delivery Systems And Piston Assemblies	Long Acting Peptide Tyrosine Tyrosine (PYY) Analogs And Methods Of Use	Long Acting Glucagon Like Polypeptide-1 (GLP-1) Receptor Agonists And Methods Of Use	Human Amylin Analog Polypeptides And Methods Of Use	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Implant Placement Guide	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Title/Mark
United Kingdom	United Kingdom	United Kingdom	United Kingdom	United Kingdom	United Kingdom	United Kingdom	United Kingdom	United Kingdom	United Kingdom	Turkey	Turkey	Taiwan	Taiwan	Taiwan	Taiwan	Taiwan	Switzerland	Switzerland	Country
17186130.5	10819152.9	08743213.4	07811174.7	11165432.3	11165433.1	07797884.9	03818515.6	03760392.5	02742222.9	10819152.9	11165432.3	110113745	110147341	108136940	111102678	106116000	142893	10819152.9	Application No
09/21/2010	09/21/2010	04/22/2008	08/08/2007	08/08/2007	05/10/2011	05/30/2007	06/25/2003	06/17/2003	06/21/2002	09/21/2010	08/08/2007	04/16/2021	12/17/2021	10/14/2019	05/15/2017	05/15/2017	11/30/2016	09/21/2010	Application Date
08/14/2017	03/06/2012	10/12/2009	01/22/2009	05/10/2011	01/22/2009	11/12/2008	06/25/2003	01/06/2005	01/21/2004	03/06/2012	05/10/2011				01/21/2022			03/06/2012	National Filing Date
3323423	2462246	2157967	2049081	2359808	2363112	2020990	1551493	1536767	1401395	2462246	2359808					1754643	142893	2462246	Patent No
06/17/2020	09/06/2017	01/16/2013	11/14/2012	05/22/2013	10/10/2018	09/22/2010	10/31/2007	08/08/2007	04/20/2005	09/06/2017	05/22/2013	01/01/1900	01/01/1900	01/01/1900	01/01/1900	02/11/2022	01/13/2017	09/06/2017	Grant Date
	2462246			2359808			1551493		1401395	2462246	2359808	202204390		202028228	202219061	201808989		2462246	Publication No
	06/13/2012	01/01/1900	01/01/1900	08/24/2011	01/01/1900		07/13/2005	01/01/1900	03/31/2004	06/13/2012	08/24/2011	02/01/2022	01/01/1900	08/01/2020	05/16/2022	03/16/2018		06/13/2012	Publication Date
Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Published	Pending	Published	Published	Issued	Issued	Issued	Status

606214	606215	606238	606216	606228	705176	607678B	606657B	606628B	606630B	606627B	606631B	606709B	606704B	606703В	606702B	606698B	606706B	Matter No
102487-014CON6	102487-014CON5	102487-014CON4	102487-014CON3	102487-014CON2	102487- 048WOEPGB	102487-043EPEM6	102487-043EPEM5	102487-043EPEM4	102487-043EPEM3	102487-043EPEM2	102487-043EPEM1	102487- 043DEPEM6	102487- 043DEPEM5	102487- 043DEPEM4	102487- 043DEPEM3	102487- 043DEPEM2	102487- 043DEPEM1	IP Ref No
ITCA-014/C06US	ITCA-014/C05US	ITCA-014/C04US	ITCA-014/C03US	ITCA-014/C02US		ITCA- 043/02EM6	ITCA- 043/02EM5	ITCA- 043/02EM4	ITCA- 043/02EM3	ITCA- 043/02EM2			ITCA- 043/03EM5	ITCA- 043/03EM4	ITCA- 043/03EM3	ITCA- 043/03EM2		Client Ref No
Stable Non-Aqueous Single Phase Viscous Vehicles And Formulations Utilizing Such Vehicles	Stable Non-Aqueous Single Phase Viscous Vehicles And Formulations Utilizing Such Vehicles	Stable Non-Aqueous Single Phase Viscous Vehicles and Formulations Utizing Such Vehicles	Stable Non-Aqueous Single Phase Viscous Vehicles And Formulations Utilizing Such Vehicles	Stable Non-Aqueous Single Phase Viscous Vehicles And Formulations Utilizing Such Vehicles	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Implant Placement Guide	Implant Removal Tool	Title/Mark										
United States of America	United States of America	United States of America	United States of America	United States of America	United Kingdom	United Kingdom	United Kingdom	United Kingdom	United Kingdom	United Kingdom	United Kingdom	United Kingdom	United Kingdom	United Kingdom	United Kingdom	United Kingdom	United Kingdom	Country
13/454.063	13/219,262	13/043,288	12/077,117	12/075,435	17725143.6	003494970-0006	003494970-0005	003494970-0004	003494970-0003	003494970-0002	003494970-0001	003495787-0006	003495787-0005	003495787-0004	003495787-0003	003495787-0002	003495787-0001	Application No
04/23/2012	08/26/2011	03/08/2011	03/17/2008	03/11/2008	05/15/2017	12/01/2016	12/01/2016	12/01/2016	12/01/2016	12/01/2016	12/01/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	Application Date
					12/04/2018													National Filing Date
8.268.341	8,992,961	8,173,150	8,048,438	7,919,109	3458084	003494970-0006	003494970-0005	003494970-0004	003494970-0003	003494970-0002	003494970-0001	003495787-0006	003495787-0005	003495787-0004	003495787-0003	003495787-0002	003495787-0001	Patent No
09/18/2012	03/31/2015	05/08/2012	11/01/2011	04/05/2011	04/01/2020	12/01/2016	12/01/2016	12/01/2016	12/01/2016	12/01/2016	12/01/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	12/02/2016	Grant Date
2012/0208754 A1	2011/0308061 A1	2011/0160708 A1	2008/0226625 A1	2008/0226689A1														Publication No
08/16/2012	12/22/2011	06/30/2011	09/18/2008	09/18/2008	01/01/1900													Publication Date
Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Status

ø.
12
2
-
$\circ$
4

157922104.2	605320	606236	605317	606219	606225	606220	606221	607550	606237	606244	606222	606223	606226	606227	Matter No
2	102487-028CON	102487-028ACON2	102487-028	102487-026	102487-025	102487-024	102487-021US	102487-021CON	102487-019DIV	102487-019	102487-017	102487-016CON2	102487-015CON	102487-015	IP Ref No
	ITCA-028/C01US	ITCA-028/X01US	ITCA-028/001US	ITCA-026/001US	ITCA-025/001US	ITCA-024/001US	ITCA-021/001US	ITCA-021/C01US	ITCA-019/D01US	ITCA-019/001US	ITCA-017/001US	ITCA-016/C02US	ITCA-015/C01US	ITCA-015/001US	Client Ref No
	Composition And Dosage Form Comprising A Particle Formulation And Suspending Vehicle	Particle Formulations For Use In Pharmaceutical Compositions	Composition And Dosage Form Comprising An Interferon Particle Formulation And Suspending Vehicle	Osmotic Pump With Self-Retaining, Fast- Start Membrane Plug	Osmotically Driven Active Agent Delivery Device Providing an Ascending Release Profile	Osmotic Pump with Means for Dissipating Internal Pressure	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Osmotic Delivery Device Having A Two- Way Valve And A Dynamically Self- Adjusting Flow Channel	Osmotic Delivery Device Having A Two- Way Valve And A Dynamically Self- Adjusting Flow Channel	Osmotic Implant With Membrane And Membrane Retention Means	Method For Treating Hepatitis C Virus With Omega Interferon	Valve For Osmotic Devices	Valve For Osmotic Devices	Title/Mark
	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	Country
26	12/655,397	13/091,970	10/988,716	10/969,753	10/953,895	10/814,801	10/606,407	11/219,960	11/237,489	10/302,104	10/173,992	10/982,532	10/310,742	09/748,099	Application No
	12/29/2009	04/21/2011	11/15/2004	10/20/2004	09/29/2004	03/31/2004	06/25/2003	09/06/2005	09/27/2005	11/21/2002	06/18/2002	11/05/2004	12/04/2002	12/21/2000	Application Date
															National Filing Date
	7,964,183	8,398,967	7,731,947	7,407,499	7,241,457	7,207,982	6,939,556	7,112,335	7,316,680	7,014,636	7,163,688	7,727,519	6,682,522	6,508,808	Patent No
	06/21/2011	03/19/2013	06/08/2010	08/05/2008	07/10/2007	04/24/2007	09/06/2005	09/26/2006	01/08/2008	03/21/2006	01/06/2007	06/01/2010	01/27/2004	01/21/2003	Grant Date
	2010-0112070 A1	2011/0208168A1	2005-0112188 A1	2005/0095284 A1	2005/0107772A1	20050070884	2004-0019345	2006-0111693 A1	2006/0116665A1	2004-0102762 A1		2005/0201980A1	2003/0093063A1		Publication No
	05/06/2010	08/25/2011	05/26/2005	05/05/2005	05/19/2005	03/31/2005	01/29/2004	05/25/2006	06/01/2006	05/27/2004		09/15/2005	05/15/2003		Publication Date
	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Status

157922104	605391

605391	605380	607549	606247	606248	605326	605330	605331	605328	605324	605325	605329	605321	605319	Matter No
102487-034CON	102487-034	102487-033CON	102487-033	102487-032	102487-031USCON	102487-031DIV3	102487-031DIV2	102487-031DIV	102487-031CON4	102487-031CON3	102487-031	102487-028CON3	102487-028CON2	IP Ref No
ITCA-034/C01US	ITCA-034/001US	ITCA-033/C01US	ITCA-033/001US	ITCA-032/X01US	ITCA-031/C01US	ITCA-031/D03US	ITCA-031/D02US	ITCA-031/D01US	ITCA-031/C04US	ITCA-031/C03US	ITCA-031/001US	ITCA-028/C03US	ITCA-028/C02US	Client Ref No
Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator	Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator	Polyoxaester Suspending Vehicles For Use With Implantable Delivery Systems	Polyoxaester Suspending Vehicles For Use With Implantable Delivery Systems	Implantable Device For Continuous Delivery Of Interferon	Solvent/Polymer Solutions As Suspension Vehicles	Solvent/Polymer Solutions As Suspension Vehicles	Solvent/Polymer Solutions As Suspension Vehicles	Osmotic Drug Delivery Devices Containing Suspension Formulations Comprising Particles Having Active Agents And Nonaqueous Single-Phase Vehicles	Solvent/Polymer Solutions As Suspension Vehicles	Solvent/Polymer Solutions As Suspension Vehicles	Solvent/Polymer Solutions As Suspension Vehicles	Methods Of Manufacturing Viscous Liquid Pharmaceutical Formulations	Composition And Dosage Form Comprising A Particle Formulation And Suspending Vehicle	Title/Mark
United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	Country
13/433,287	11/755,494	13/100,016	11/374,228	11/347,601	13/158,137	13/647,873	13/647,228	12/925,864	14/749,178	13/526,375	11/347,562	13/598,405	13/090,947	Application No
03/29/2012	05/30/2007	05/03/2011	03/13/2006	02/03/2006	06/10/2011	10/09/2012	10/08/2012	11/01/2010	06/24/2015	06/18/2012	02/03/2006	08/29/2012	04/20/2011	Application Date
														National Filing Date
8,273,365	8,052,996	8,114,430	7,959,938	7,655,254	8,206,745	9,095,553	8,460,694	8,211,467	9,526,763	8,440,226	8,114,437	9,724,293	8,257,691	Patent No
09/25/2012	11/08/2011	02/14/2012	06/14/2011	02/02/2010	06/26/2012	08/04/2015	06/11/2013	07/03/2012	12/27/2016	05/14/2013	02/14/2012	08/08/2017	09/04/2012	Grant Date
2012-0184945 A1	2007/0281024 A1	2011-0264076 A1	2006/0246138A1	2006/0251618A1	2011-0264077 A1	2013-0034210 A1	2013-0035670 A1	2011-0104111 A1	2015-0290291 A1	2012-0259318 A1	2006-0193918 A1	2013/0052237A1	2011-0195097 A1	Publication No
07/19/2012	12/06/2007	10/27/2011	11/02/2006	11/09/2006	10/27/2011	02/07/2013	02/07/2013	05/05/2011	10/15/2015	10/11/2012	08/31/2006	02/28/2013	08/11/2011	Publication Date
Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Status

-	а
V	o.
1	3
1	٠
-	_
C	_
4	_

157922104.2	726169	611562	605246	605497	605389	605280	605387	605390	605385	605386	605381	605382	605383	605392	Matter No
2	102487-036CON5	102487-036CON4	102487-036CON3	102487-036CON2	102487-036	102487-035CON3	102487-035CON2	102487-035CON	102487-035	102487-034DIV	102487-034CON5	102487-034CON4	102487-034CON3	102487-034CON2	IP Ref No
	ITCA-036/C05US	ITCA-036/C04US	ITCA-036/C03US	ITCA-036/C02US	ITCA-036/001US	ITCA-035/C03US	ITCA-035/C02US	ITCA-035/C01US	ITCA-035/001US	ITCA-034/D01US	ITCA-034/C05US	ITCA-034/C04US	ITCA-034/C03US	ITCA-034/C02US	Client Ref No
	Suspension Formulation Comprising An Insulinotropic Peptide	Suspension Formulation Comprising An Insulinotropic Peptide	Method Of Manufacturing An Osmotic Delivery Device	Osmotic Delivery Device Comprising An Insulinotropic Peptide And Uses Thereof	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Osmotic Delivery Systems And Piston Assemblies For Use Therein	Osmotic Delivery Systems And Piston Assemblies For Use Therein	Osmotic Delivery Systems And Piston Assemblies For Use Therein	Osmotic Delivery Systems And Piston Assemblies For Use Therein	Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator	Title/Mark				
	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	Country
28	17/671,232	16/441,803	15/612,581	15/291,523	12/148,896	14/316,969	12/930,950	12/658,570	11/890,836	13/209,328	14/632,700	13/898,358	13/740,187	13/601,939	Application No
	02/14/2022	06/14/2019	06/02/2017	10/12/2016	04/22/2008	06/27/2014	01/19/2011	02/09/2010	08/08/2007	08/12/2011	02/26/2015	05/20/2013	01/12/2013	08/31/2012	Application Date
															National Filing Date
		11,246,913	10,363,287	9,682,127	8,299,025	10,527,170	8,801,700	7,879,028	7,682,356	8,158,150	9,539,200	8,992,962	8,470,353	8,367,095	Patent No
	01/01/1900	02/15/2022	07/30/2019	06/20/2017	10/30/2012	01/07/2020	08/12/2014	02/01/2011	03/23/2010	04/17/2012	01/10/2017	03/31/2015	06/25/2013	02/05/2013	Grant Date
		2020/0054717A1	2017-0368145 A1	2017-0072022 A1	2008-0260840 A1	2014/0378900A1	2011-0166554 A1	2010-0185184 A1	2008-0091176 A1	2011-0301576 A1	2015-0231062 A1	2013-0247376 A1	2013-0138089 A1	2012-0330282 A1	Publication No
	01/01/1900	02/20/2020	12/28/2017	03/16/2017	10/23/2008	12/25/2014	07/07/2011	07/22/2010	04/17/2008	12/08/2011	08/20/2015	09/26/2013	05/30/2013	12/27/2012	Publication Date
	Pending	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Status

-	a
v	5
N	5
1	٥
$\vdash$	-
	>
4	`

157922104.2	712874	605286	605282	606246	605283	712156	605230	605233	605402	605396	605278	605398	605397	605395	Matter No
2	102487-043CON	102487-043	102487-042CON	102487-042	102487-040CON2	102487-039CON4	102487-039CON3	102487-039CON2	102487-039	102487-037DIV	102487-037CON3	102487-037CON	102487-037	102487-036DIV	IP Ref No
		ITCA-043/001US	ITCA-042/C01US	ITCA-042/001US	ITCA-040/C02US	ITCA-039/C04US	ITCA-039/C03US	ITCA-039/C02US	ITCA-039/001US	ITCA-037/D01US	ITCA-037/C03US	ITCA-037/C01US	ITCA-037/001US	ITCA-036/D01US	Client Ref No
	Implant Placement And Removal Systems	Implant Placement And Removal Systems	Therapeutic Methods For The Treatment Of Diabetes And Related Conditions For Patients With High Baseline HbA1c	Therapeutic Methods For The Treatment Of Diabetes And Related Conditions For Patients With High Baseline HbA1c	Compositions, Devices And Methods Of Use Thereof For The Treatment Of Cancers	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Osmotic Delivery Device Comprising An Insulinotropic Peptide And Uses Thereof	Title/Mark
	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	Country
29	17/121,576	15/172,132	15/868,708	14/871,420	15/597,788	17/121,359	16/029,232	15/242,732	12/924,175	13/689,410	15/923,720	14/580,320	12/378,341	12/927,432	Application No
	12/14/2020	06/02/2016	01/11/2018	09/30/2015	05/17/2017	12/14/2020	07/06/2018	08/22/2016	09/21/2010	11/29/2012	03/16/2018	12/23/2014	02/12/2009	11/15/2010	Application Date
															National Filing Date
		10,925,639	10,583,080	9,889,085	10,159,714		10,869,830	10,231,923	8,298,561	8,926,595	10,441,528	9,572,889	8,343,140	8,940,316	Patent No
	01/01/1900	02/23/2021	03/10/2020	02/13/2018	12/25/2018	01/01/1900	12/22/2020	03/19/2019	10/30/2012	01/06/2015	10/15/2019	02/21/2017	01/01/2013	01/27/2015	Grant Date
	2021/0307782A1	2016-0354115 A1	2018/0256491 A1		2017/0252409A1	2021/0236413A1	2019/0105259A1	2016/0354305A1	2011-0076317 A1	2013-0090287 A1	2018/0256492 A1	2015-0111818 A1	2009-0202608 A1	2012-0178687 A1	Publication No
	10/07/2021	12/08/2016	09/13/2018		09/07/2017	08/05/2021	04/11/2019	12/08/2016	03/31/2011	04/11/2013	09/13/2018	04/23/2015	08/13/2009	07/12/2012	Publication Date
	Published	Issued	Issued	Issued	Issued	Published	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Issued	Status

-	а
V	o.
1	3
1	٠
-	_
C	_
4	_

724936	617097	710908	605307	613816	720191	617297	605309	606517	605649	606021	607017	605654	605646	Matter No
102487-056	102487-055	102487-052CON	102487-052	102487-051US	102487-048CON2	102487-048CON	102487-048	102487-043DDIV2	102487-043DDIV	102487-043D3	102487-043D2DIV	102487-043D2	102487-043D	IP Ref No
	ITCA-055/N01US	ITCA-052/C01US	ITCA-052/N01US	ITCA-051/N01US		ITCA-048/N01US	ITCA-048/N01US		ITCA-043/02US2	ITCA-043/04US1	ITCA-043/03US1	ITCA-043/03US1	ITCA-043/02US1	Client Ref No
Long Acting Glucagon Like Polypeptide-1 (GLP-1) Receptor Agonists And Methods Of Use	Human Amylin Analog Polypeptides And Methods Of Use	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist And Co-administration Of A Drug	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist And Co-administration Of A Drug	Apparatus And Methods For Administration Of A Nauseogenic Compound From A Drug Delivery Device	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Implant Placement Guide	Implant Placement Guide	Implant Removal Tool And Assembly	Implant Removal Tool	Implant Removal Tool	Implant Placement Guide	Title/Mark
United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	United States of America	Country
17/553.381	16/598,915	17/069,521	15/861,258	16/491,275	17/538,507	16/667,502	15/595,809	29/667,595	29/604,792	29/656,639	29/699,323	29/566,822	29/566,823	Application No
12/16/2021	10/10/2019	10/13/2020	01/03/2018	09/05/2019	11/30/2021	10/29/2019	05/15/2017	10/23/2018	05/19/2017	07/13/2018	07/24/2019	06/02/2016	06/02/2016	Application Date
				09/05/2019										National Filing Date
			10,835,580			11,214,607	10,501,517		D835,783	D933,219	D912,249	D860,451	D840,030	Patent No
01/01/1900	01/01/1900	01/01/1900	11/17/2020	01/01/1900	01/01/1900	01/04/2022	12/10/2019	01/01/1900	12/11/2018	10/12/2021	03/02/2021	09/17/2019	02/05/2019	Grant Date
	2020/0115430A1	2021/0236602A1	2018/0185451 A1	2020/0188479A1		2020/0299350A1	2018-0009871 A1							Publication No
01/01/1900	04/16/2020	08/05/2021	07/05/2018	06/18/2020	01/01/1900	09/24/2020	01/11/2018	01/01/1900	01/01/1900	01/01/1900				Publication Date
Pending	Published	Published	Issued	Published	Pending	Issued	Issued	Allowed	Issued	Issued	Issued	Issued	Issued	Status

<b>√</b> 1
ø
12
2
$\vdash$
0
4

605193	605190	605189	605080	605069	605066	605057	605042	605035	605032	605031	605028	717075	727769	No
102487-035WOEP	102487-054-1	102487-054	102487- 039WONZDIV2	102487- 039WOJPDIV3	102487- 039WOKRDIV	102487- 039WOEPDIV	102487-039WOIN	102487- 036WOCNDIHK	102487- 036WOCNDIV2	102487- 036WOCNDIV2HK	102487- 036WOCNDIV	102487-058	102487-057-1c	IP Ref No
ITCA-035/N01EP	ITCA-054/P01US		ITCA-039/D02NZ	ITCA-039/D03JP	ITCA-039/D01KR	ITCA-039/D01EP	ITCA-039/N01IN	ITCA-036/D01HK	ITCA- 036/D02CN	ITCA-036/D02HK	ITCA- 036/D01CN			Client Ref No
Osmotic Delivery Systems And Piston Assemblies	Methods For Treatment Of Type 2 Diabetes In Patients Previously Treated With A GLP-1 Agonist	Methods For Treatment Of Type 2 Diabetes In Patients Previously Treated With A GLP-1 Agonist	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Long Acting Peptide Tyrosine Tyrosine (PYY) Analogs And Methods Of Use	High Concentration Formulations, Devices Comprising The Same, And Methods Of Use	Title/Mark
European Patent Convention	United States	United States	New Zealand	Japan	Republic of Korea	European Patent Convention	India	Hong Kong	China P.R.	Hong Kong	China P.R.	United States of America	United States of America	Country
07811174.7	62/559,427		713860	2018-132384	10-2014-7036345	17186130.5	2639/DELNP/2012	15100822.7	201610052787.5	16114320.4	201410262400.X	17/233,111	63/318,586	Application No
8/8/2007	9/15/2017		11/2/2015	7/12/2018	12/24/2014	8/14/2017	9/21/2010	7/8/2010	4/22/2008	12/15/2016	4/22/2008	04/16/2021	03/10/2022	Date
1/22/2009			3/9/2012	3/26/2012	3/26/2012	3/6/2012	3/26/2012		4/22/2008					Filing Date
2049081						3323423								Patent No
11/14/2012						6/17/2020						01/01/1900		Grant Date
												2022/0002371A1		Publication No
				11/1/2018		5/23/2018	8/31/2016	8/27/2014	6/22/2016	9/22/2017	8/27/2014	01/06/2022		Date
Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Allowed	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Published	Pending	Status

605620	605596	605576	605435	605312	605311	605310	605300	605285	605279	605236	605212	605195	Matter No
102487-048WO	102487- 035WOEPDIV	102487-040WOCA	102487- 035WOEPDIV2	102487-044	102487-047	102487-020CON	102487-046	102487-045-1	102487-028CON4	102487-038CON2	102487-034CON6	102487- 031USCON6	IP Ref No
ITCA- 048/N01WO	ITCA-035/D01EP	ITCA-040/N01CA	ITCA-035/D02EP	ITCA-044/N01US	ITCA-047/N01US	ITCA-020/C01US	ITCA-046/N01US	ITCA-045/P01US	ITCA-028/C04US	ITCA-038/C02US	ITCA-034/C06US	ITCA-031/C06US	Client Ref No
Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Osmotic Delivery Systems And Piston Assemblies	Compositions, Devices And Methods Of Use Thereof For The Treatment Of Cancers	Osmotic Delivery Systems And Piston Assemblies	Therapeutic Methods For The Treatment Of Diabetes And Related Conditions For Patients Receiving Metformin Monotherapy	Therapeutic Methods For The Treatment Of Diabetes And Related Conditions For Patients With Renal Impairment	Osmotic Delivery System With Early Zero Order Push Power Engine	Methods And Apparatuses For Management Of Healthcare Services And Products Transactions Thereof And Methods Of Treatment	High Concentration Formulations, Devices Comprising The Same, And Methods Of Use	Methods Of Manufacturing Viscous Liquid Pharmaceutical Formulations	Highly Concentrated Drug Particles, Formulations, Suspensions And Uses Thereof	Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator	Solvent/Polymer Solutions As Suspension Vehicles	Title/Mark
Patent Cooperation Treaty	European Patent Convention	Canada	European Patent Convention	United States	United States	United States	United States	United States	United States	United States	United States	United States	Country
PCT/US17/32714	11165432.3	2823721	11165433.1	15/239,311	15/388,648	11/389,734	15/344,318	62/658,167	15/658,965	15/408,112	15/347,261	15/626,483	Application No
5/15/2017	5/10/2011	2/14/2012	5/10/2011	8/17/2016	12/22/2016	3/27/2006	11/4/2016	4/16/2018	7/25/2017	1/17/2017	11/9/2016	6/19/2017	Application Date
	1/22/2009	8/13/2013	1/22/2009										National Filing Date
	2359808	2823721	2363112										Patent No
	5/22/2013	7/7/2020	10/10/2018										Grant Date
													Publication No
11/23/2017	8/24/2011					8/17/2006			11/9/2017	5/4/2017	6/29/2017	12/7/2017	Publication Date
Converted	Abandoned	Allowed	Abandoned	Abandoned		Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Status

ø
ひ
2
$\vdash$
0
4

157922104.2	606077	606063	606061	606060	606016	606014	605897	605895	605840	605625	605624	605623	605622	605621	Matter No
2	102487- 013WOCNHK	102487-013WOEP	102487- 010WOEPDIV3	102487- 010WOCNHK	102487-048WOZA	102487-048WOSG	102487- 035WOEPDIV3	102487-038WOEP	102487-055-1	102487-008WOKR	102487-008WOEP	102487-008WOJP	102487-008WOCN	102487-008WOCA	IP Ref No
	ITCA- 013/N01HK	ITCA-013/N01EP	ITCA-010/D03EP	ITCA- 010/N01HK	ITCA-048/N01ZA	ITCA-048/N01SG	ITCA-035/D03EP	ITCA-038/N01EP	ITCA-055/P01US	ITCA-008/N01KR	ITCA-008/N01EP	ITCA-008/N01JP	ITCA- 008/N01CN	ITCA-008/N01CA	Client Ref No
	Osmotic Delivery System Having Space Efficient Piston	Osmotic Delivery System Having Space Efficient Piston	Implanter Device For Subcutaneous Implants	Implanter Device For Subcutaneous Implants	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Osmotic Delivery Systems And Piston Assemblies	Highly Concentrated Drug Particles, Formulations, Suspensions And Uses Thereof	Human Amylin Analog Polypeptides And Methods Of Use	Rate Controlling Membranes For Controlled Drug Delivery Devices	Rate Controlling Membranes For Controlled Drug Delivery Devices	Rate Controlling Membranes For Controlled Drug Delivery Devices	Rate Controlling Membranes For Controlled Drug Delivery Devices	Rate Controlling Membranes For Controlled Drug Delivery Devices	Title/Mark
	European Patent Convention	European Patent Convention	Hong Kong	South Africa	Singapore	European Patent Convention	European Patent Convention	United States	Patent Cooperation Treaty	Republic of Korea	European Patent Convention	Japan	China P.R.	Canada	Country
33	02101884.5	99967575.4		01102734.6	2018/07434	112018101025	18164515.1	09741052.6	62/744,236	10-2000-7006892	98960688.4	2000-525087	98812475.0	2315890	Application No
	12/21/1999	12/21/1999		12/15/1998	5/15/2017	5/15/2017	3/28/2018	10/14/2009	10/11/2018	12/3/1998	12/3/1998	12/3/1998	12/3/1998	12/3/1998	Application Date
	7/30/2001	6/29/2000	4/18/2001	11/6/2018	11/13/2018	3/12/2008	5/9/2011			6/21/2000	6/22/2000		6/20/2000	6/21/2000	National Filing Date
	HK1040916	1140014	1300174	1032015						10-0576583-0000	1041975	4215188	ZL98812475.0	2315890	Patent No
	10/3/2003	3/19/2003	2/16/2005	2/25/2005						5/4/2006	9/4/2002	11/14/2008	5/21/2008	8/11/2009	Grant Date
															Publication No
	6/28/2002		4/9/2003				1/2/2019	8/3/2011		4/25/2001	10/11/2000	12/18/2001	1/31/2001		Publication Date
	Abandoned	Abandoned	Allowed	Expired			Abandoned	Abandoned	Converted	Expired	Expired	Expired	Expired	Expired	Status

ø.
12
2
$\vdash$
0
4

606180	606167	606159	606154	606153	606152	606151	606150	606149	606148	606127	606123	606109	606083	No
102487-013WOAU	102487-010WOCN	102487-010WONZ	102487- 010WONZDIV	102487-010WOJP	102487-010WOMX	102487-010WOKR	102487-010WOIL	102487-010WOEP	102487-010WOAU	102487- 010WONZDIV3	102487- 010WOILDIV2	102487- 014WOEPDIV	102487- 014WOCNDIVHK	IP Ref No
ITCA- 013/N01AU	ITCA- 010/N01CN	ITCA-010/N01NZ	ITCA-010/D01NZ	ITCA-010/N01JP	ITCA- 010/N01MX	ITCA-010/N01KR	ITCA-010/N01IL	ITCA-010/N01EP	ITCA- 010/N01AU	ITCA-010/D03NZ	ITCA-010/D02IL	ITCA-014/D01EP	ITCA-014/D01HK	Client Ref No
Osmotic Delivery System Having Space Efficient Piston	Implanter Device For Subcutaneous Implants	Implanter Device For Subcutaneous Implants	Implanter Device For Subcutaneous Implants	Implanter Device For Subcutaneous Implants	Implanter Device For Subcutaneous Implants	Implanter Device For Subcutaneous Implants	Implanter Device For Subcutaneous Implants	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Title/Mark				
China P.R.	New Zealand	New Zealand	Japan	Mexico	Republic of Korea	Israel	European Patent Convention	Australia	New Zealand	Israel	European Patent Convention	Hong Kong	Hong Kong	Country
2000023836	98812689.3	505479	525373	2000-526258	PA/a/2000/006440	1020007007242	137095	98963214.6	18284/99	545638	167247	06075430.6	06113414.5	Application No
12/21/1999	12/15/1998	12/15/1998	12/15/1998	12/15/1998	12/15/1998	12/15/1998	12/15/1998	12/15/1998	12/15/1998	12/15/1998	3/3/2005	2/27/2006	12/6/2006	Date
6/26/2000	6/29/2000	4/16/2003	6/29/2000	6/28/2000	6/28/2000	6/29/2000	7/4/2000	6/29/2000	2/28/2006		9/7/2001		3/12/2002	Filing Date
771132	ZL98812689.3	505479	525373	4188560	221764	546982	137095	1044032	746638	545638	167247	1666026	HK1094528	Patent No
6/24/2004	7/13/2005	11/3/2003	4/7/2005	9/19/2008	7/27/2004	10/26/2005	4/16/2006	4/21/2004	8/15/2002	2/8/2008	9/16/2009	12/21/2011	6/8/2012	Grant Date
														Publication No
	2/7/2001							10/18/2000			2/5/2006	6/7/2006		Date
Abandoned	Expired	Expired	Expired	Expired	Expired	Expired	Expired	Expired	Expired	Expired	Expired	Abandoned PATE	Abandoned	Status

606217	606213	606212	606211	606210	606209	606208	606207	606205	606204	606183	606182	606181	Matter No
102487-014	102487-014CON7	102487-009USDIV2	102487-012	102487-009USDIV	102487-012USCON	102487-009	102487-008US	102487-007USCON	102487-006USDIV2	102487-013WOCA	102487-013WONZ	102487-013WOJP	IP Ref No
ITCA-014/001US	ITCA-014/C07US	ITCA-009/D02US	ITCA-012/001US	ITCA-009/D01US	ITCA-012/C01US	ITCA-009/001US	ITCA-008/001US	ITCA-007/C01US	ITCA-006/D02US	ITCA-013/N01CA	ITCA-013/N01NZ	ITCA-013/N01JP	Client Ref No
Stable Non-Aqueous Single Phase Viscous Vehicles And Formulations Utilizing Such Vehicles	Stable Non-Aqueous Single Phase Viscous Vehicles And Formulations Utilizing Such Vehicles	Osmotic Delivery System With Membrane Plug Retention Mechanism	Trocar For Inserting Implants	Osmotic Delivery System With Membrane Plug Retention Mechanism	Trocar For Inserting Implants	Osmotic Delivery System With Membrane Plug Retention Mechanism	Rate Controlling Membranes For Controlled Drug Delivery Devices	Osmotic Delivery System, Osmotic Delivery System Semipermeable Body Assembly, And Method For Controlling Delivery Rate Of Beneficial Agents From Osmotic Delivery Systems	Osmotic Delivery System Flow Modulator Apparatus And Method	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery Systems And Piston Assemblies	Osmotic Delivery System Having Space Efficient Piston	Title/Mark
United States	United States	United States	United States	United States	United States	United States	United States	United States	Canada	New Zealand	Japan	Australia	Country
09/497,422	13/596,971	09/858,632	09/296,582	09/858,631	10/191,700	09/217,823	09/213,213	09/859,428	10/994,615	2356860	512671	2000-591975	Application No
2/3/2000	8/28/2012	5/17/2001	4/23/1999	5/17/2001	7/8/2002	12/22/1998	12/17/1998	5/18/2001	11/22/2004	12/21/1999	12/21/1999	12/21/1999	Application Date
									6/28/2001	6/29/2001		6/29/2001	National Filing Date
7,258,869	8,372,424	6,899,887	7,063,681	6,976,981	7,329,242	6,270,787	6,375,978	6,923,800	7,407,500	2356860	512671	4383674	Patent No
8/21/2007	2/12/2013	5/31/2005	6/20/2006	12/20/2005	2/12/2008	8/7/2001	4/23/2002	8/2/2005	8/6/2008	11/7/2006	3/29/2004	10/2/2009	Grant Date
													Publication No
	12/20/2012	9/20/2001		9/13/2001				10/4/2001	6/16/2005		12/19/2003		Publication Date
Abandoned	Allowed	Expired	Expired	Expired	Expired	Expired	Expired	Expired	Expired	Abandoned	Abandoned PATE	Abandoned	Status

ø
12
13
-
0
4

606310	606309	606306	606305	606304	606303	606250	606249	606245	606240	606239	606230	606229	606218	No
102487- 010EPDIV3ES	102487- 010EPDIV3NL	102487-008EPIE	102487-008EPGB	102487-008EPFR	102487-008EPDE	102487- 014WOEPDIVGB	102487- 014WOEPDIVCH	102487-014WOAU	102487-013	102487-013CON	102487-013CON2	102487-013CON3	102487-010	IP Ref No
ITCA-010/D03ES	ITCA-010/D03NL	ITCA-008/N01IE	ITCA- 008/N01GB	ITCA-008/N01FR	ITCA-008/N01DE	ITCA- 014/D01GB	ITCA- 014/D01CH	ITCA- 014/N01AU	ITCA-013/001US	ITCA-013/C01US	ITCA-013/C02US	ITCA-013/C03US	ITCA-010/001US	Client Ref No
Implanter Device For Subcutaneous Implants	Implanter Device For Subcutaneous Implants	Rate Controlling Membranes For Controlled Drug Delivery Devices	Rate Controlling Membranes For Controlled Drug Delivery Devices	Rate Controlling Membranes For Controlled Drug Delivery Devices	Rate Controlling Membranes For Controlled Drug Delivery Devices	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Stable Non-Aqueous Single Phase Viscous Vehicles And Formulations Utilizing Such Vehicles	Osmotic Delivery Systems And Piston Assemblies	Implanter Device For Subcutaneous Implants	Title/Mark			
Netherlands	Ireland	Great Britain	France	Germany	Great Britain	Switzerland	Australia	United States	United States	United States	United States	United States	United States	Country
02080493.6	02080493.6	98960688.4	98960688.4	98960688.4	98960688.4	06075430.6	06075430.6	2000034816	09/472,600	10/354,142	10/959,489	11/353,842	09/217,824	Application No
12/15/1998	12/15/1998	12/3/1998	12/3/1998	12/3/1998	12/3/1998	2/27/2006	2/27/2006	2/2/2000	12/27/1999	1/30/2003	10/5/2004	2/14/2006	12/22/1998	Date
6/29/2000	6/22/2000	6/22/2000	6/22/2000	6/22/2000	9/7/2001	9/7/2001	8/8/2001							Filing Date
1300174	1300174	1041975	1041975	1041975	69807748.2	1666026	1666026	775904	6,544,252	6,872,201	6,997,922	7,235,068	6190350	Patent No
2/16/2005	2/16/2005	9/4/2002	9/4/2002	9/4/2002	9/4/2002	12/21/2011	12/21/2011	12/2/2004	4/8/2003	3/29/2005	2/14/2006	6/26/2007	2/20/2001	Grant Date
														Publication No
4/9/2003	4/9/2003	10/11/2000	10/11/2000	10/11/2000	10/11/2000	6/7/2006	6/7/2006				4/21/2005	6/15/2006		Date
Expired	Expired	Expired	Expired	Expired	Expired	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Expired	Status

606329	606326	606324	606321	606320	606319	606318	606317	606315	606314	606313	606312	606311	Matter No
102487- 010EPDIV3IE	102487- 010EPDIV3DE	102487-010EPES	102487- 010EPDIVFR	102487- 010EPDIVGB	102487- 010EPDIV3CH	102487-051WO	102487-052WO	102487- 010EPDIV3GB	102487-010ЕРСН	102487- 010EPDIVDE	102487- 010EPDIV3FR	102487- 008WOEPCH	IP Ref No
ITCA-010/D03IE	ITCA-010/D03DE	ITCA-010/N01ES	ITCA-010/D01FR	ITCA- 010/D01GB	ITCA- 010/D03CH	ITCA- 051/N01WO	ITCA- 052/N01WO	ITCA- 010/D03GB	ITCA- 010/N01CH	ITCA-010/D01DE	ITCA-010/D03FR	ITCA- 008/N01CH	Client Ref No
Implanter Device For Subcutaneous Implants	Implanter Device For Subcutaneous Implants	Implanter Device For Subcutaneous Implants	Implanter Device For Subcutaneous Implants	Implanter Device For Subcutaneous Implants	Implanter Device For Subcutaneous Implants	Apparatus And Methods For Administration Of A Nauseogenic Compound From A Drug Delivery Device	Methods Comprising Continuous Administration Of A GLP-1 Receptor Aganist And Co-Administration of A Drug	Implanter Device For Subcutaneous Implants	Rate Controlling Membranes For Controlled Drug Delivery Devices	Title/Mark			
Germany	Spain	France	Great Britain	Switzerland	Patent Cooperation Treaty	Patent Cooperation Treaty	Great Britain	Switzerland	Germany	France	Switzerland	Spain	Country
02080493.6	02080493.6	98963214.6	02080491.0	02080491.0	02080493.6	PCT/US18/21594	PCT/US18/12204	02080493.6	98963214.6	02080491.0	02080493.6	98960688.4	Application No
12/15/1998	12/15/1998	12/15/1998	12/15/1998	12/15/1998	12/15/1998	3/8/2018	1/3/2018	12/15/1998	12/15/1998	12/15/1998	12/15/1998	12/3/1998	Application Date
6/29/2000	7/4/2000			6/29/2000			6/29/2000	7/4/2000		6/29/2000	6/22/2000	6/29/2000	National Filing Date
1300174	1300174	1044032	1300173		1300174			1300174	1044032	69834957.10	1300174	1041975	Patent No
2/16/2005	2/16/2005	4/21/2004	6/14/2006		2/16/2005			2/16/2005	4/21/2004	6/14/2006	2/16/2005	9/4/2002	Grant Date
													Publication No
4/9/2003	4/9/2003	10/18/2000			4/9/2003	9/13/2018	7/12/2018	4/9/2003	10/18/2000		4/9/2003	10/11/2000	Publication Date
Expired	Expired	Expired	Expired		Expired	Converted	Converted	Expired	Expired	Expired	Expired	Expired	Status

ũ	7
1	۲.
ř	۲.
à	~
2	╗
4	Z

606348	606347	606346	606344	606343	606342	606340	606339	606338	606337	606336	606335	606334	606333	Matter No
102487-013EPDE	102487-013EPDK	102487-013EPES	102487-013EPFI	102487-013EPFR	102487-013EPSE	102487-013EPPT	102487-013EPGB	102487-013EPNL	102487-013EPGR	102487-013EPMC	102487-013EPIE	102487-013EPLU	102487-013EPIT	IP Ref No
ITCA-013/N01DE	ITCA- 013/N01DK	ITCA-013/N01ES	ITCA-013/N01FI	ITCA-013/N01FR	ITCA-013/N01SE	ITCA-013/N01PT	ITCA- 013/N01GB	ITCA-013/N01NL	ITCA- 013/N01GR	ITCA- 013/N01MC	ITCA-013/N01IE	ITCA-013/N01LU	ITCA-013/N01IT	Client Ref No
Osmotic Delivery System Having Space Efficient Piston	Title/Mark													
Denmark	Spain	Finland	France	Sweden	Portugal	Great Britain	Netherlands	Greece	Monaco	Ireland	Luxembourg	Italy	Ireland	Country
99967575.4	99967575.4	99967575.4	99967575.4	99967575.4	99967575.4	99967575.4	99967575.4	99967575.4	99967575.4	99967575.4	99967575.4	99967575.4	99967575.4	Application No
12/21/1999	12/21/1999	12/21/1999	12/21/1999	12/21/1999	12/21/1999	12/21/1999	12/21/1999	12/21/1999	12/21/1999	12/21/1999	12/21/1999	12/21/1999	12/21/1999	Application Date
7/30/2001	7/30/2001	7/30/2001	7/30/2001	7/30/2001	7/30/2001	7/30/2001	7/30/2001	7/30/2001	7/30/2001	7/30/2001	7/30/2001	7/30/2001	6/29/2000	National Filing Date
1140014	1140014	1140014	1140014	1140014	1140014	1140014	1140014	1140014	1140014	1140014	1140014	1140014	1140014	Patent No
3/19/2003	3/19/2003	3/19/2003	3/19/2003	3/19/2003	3/19/2003	3/19/2003	3/19/2003	3/19/2003	3/19/2003	3/19/2003	3/19/2003	3/19/2003	3/19/2003	Grant Date
														Publication No
														Publication Date
Abandoned	Abandoned ENT	Status												

ø
12
13
-
0
4

606367	606366	606365	606364	606363	606362	606361	606360	606359	606358	606355	606354	606353	606352	No
102487- 014EPDIVGR	102487- 014EPDIVCY	102487-010EPNL	102487- 014EPDIVFR	102487-014EPDIVFI	102487- 014EPDIVBE	102487- 014EPDIVDK	102487- 014EPDIVDE	102487-010EPIE	102487- 014EPDIVAT	102487-010EPIT	102487-013EPCH	102487-013EPBE	102487-013EPAT	IP Ref No
ITCA- 014/D01GR	ITCA-014/D01CY	ITCA-010/N01NL	ITCA-014/D01FR	ITCA-014/D01FI	ITCA-014/D01BE	ITCA-014/D01DK	ITCA-014/D01DE	ITCA-010/N01IE	ITCA-014/D01AT	ITCA-010/N01IT	ITCA- 013/N01CH	ITCA-013/N01BE	ITCA-013/N01AT	Client Ref No
Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Implanter Device For Subcutaneous Implants	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Implanter Device For Subcutaneous Implants	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Implanter Device For Subcutaneous Implants	Osmotic Delivery System Having Space Efficient Piston	Osmotic Delivery System Having Space Efficient Piston	Osmotic Delivery System Having Space Efficient Piston	Title/Mark
Cyprus	Netherlands	France	Finland	Belgium	Denmark	Germany	Ireland	Austria	Italy	Switzerland	Belgium	Austria	Germany	Country
06075430.6	06075430.6	98963214.6	06075430.6	06075430.6	06075430.6	06075430.6	06075430.6	98963214.6	06075430.6	98963214.6	99967575.4	99967575.4	99967575.4	Application No
2/27/2006	2/27/2006	12/15/1998	2/27/2006	2/27/2006	2/27/2006	2/27/2006	2/27/2006	12/15/1998	2/27/2006	12/15/1998	12/21/1999	12/21/1999	12/21/1999	Date
9/7/2001	7/4/2000	9/7/2001	9/7/2001	9/7/2001	9/7/2001	9/7/2001	7/4/2000	9/7/2001	7/4/2000	7/30/2001	7/30/2001	7/30/2001	7/30/2001	Filing Date
1666026	1666026	1044032	1666026	1666026	1666026	1666026	1666026	1044032	1666026	1044032	1140014	1140014	1140014	Patent No
12/21/2011	12/21/2011	4/21/2004	12/21/2011	12/21/2011	12/21/2011	12/21/2011	12/21/2011	4/21/2004	12/21/2011	4/21/2004	3/19/2003	3/19/2003	3/19/2003	Grant Date
														Publication No
6/7/2006	6/7/2006	10/18/2000	6/7/2006	6/7/2006	6/7/2006	6/7/2006	6/7/2006	10/18/2000	6/7/2006	10/18/2000				Date
Abandoned	Abandoned	Expired	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Expired	Abandoned	Expired	Abandoned	Abandoned PAT	Abandoned	Status

	<b>J</b>
4	ō.
ı	ゝ
t	J
۲	_
0	$\overline{}$
	4

606388	606387	606386	606383	606381	606380	606379	606378	606377	606376	606375	606374	606372	606370	No
102487-016WOIL	102487-015WONZ	102487- 016WOCNHK	102487-014WOKR	102487-014WOJP	102487-014WOIL	102487-014WOCA	102487- 014EPDIVSE	102487- 014EPDIVNL	102487-014WOMX	102487-014EPDIVIE	102487- 014EPDIVMC	102487- 014EPDIVLU	102487-014EPDIVIT	IP Ref No
ITCA-016/N01IL	ITCA-015/N01NZ	ITCA- 016/N01HK	ITCA-014/N01KR	ITCA-014/N01JP	ITCA-014/N01IL	ITCA-014/N01CA	ITCA-014/D01SE	ITCA-014/D01NL	ITCA- 014/N01MX	ITCA-014/D01IE	ITCA- 014/D01MC	ITCA-014/D01LU	ITCA-014/D01IT	Client Ref No
Use Of Omega Interferon In The Manufacture Of A Medicament For Treating Hepatitis C	Valve For Osmotic Devices	Use Of Omega Interferon In The Manufacture Of A Medicament For Treating Hepatitis C	Stable Non-Aqueous Single Phase Viscous Vehicles And Formulations Utilizing Such Vehicles	Stable Non-Aqueous Single Phase Viscous Vehicles And Formulations Utilizing Such Vehicles	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Stable Non-Aqueous Single Phase Viscous Vehicles And Formulations Utilizing Such Vehicles	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Stable Non-Aqueous Single Phase Viscous Vehicles And Formulations Utilizing Such Vehicles	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Title/Mark
New Zealand	Hong Kong	Republic of Korea	Japan	Israel	Canada	Sweden	Netherlands	Mexico	Ireland	Monaco	Luxembourg	Italy	Greece	Country
155730	519753	09107318.1	10-2001-7010037	2000-596910	144755	2361424	06075430.6	06075430.6	PA/a/2001/008006	06075430.6	06075430.6	06075430.6	06075430.6	Application No
10/30/2001	12/13/2000	10/30/2001	2/2/2000	2/2/2000	2/2/2000	2/2/2000	2/27/2006	2/27/2006	2/2/2000	2/27/2006	2/27/2006	2/27/2006	2/27/2006	Date
	2/4/2005			6/8/2001	8/7/2001	9/7/2001	9/7/2001		9/7/2001	9/7/2001	9/7/2001	9/7/2001	9/7/2001	Filing Date
155730	519753	HK1068548	10-0858856	4861551	144755	2361424	1666026	1666026	244516	1666026	1666026	1666026	1666026	Patent No
5/18/2010	5/10/2004	12/18/2009	9/10/2008	11/11/2011	6/29/2010	4/28/2009	12/21/2011	12/21/2011	3/28/2007	12/21/2011	12/21/2011	12/21/2011	12/21/2011	Grant Date
														Publication No
		4/29/2005					6/7/2006	6/7/2006		6/7/2006	6/7/2006	6/7/2006	6/7/2006	Date
Abandoned		Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned	Abandoned PATE	Abandoned	Status

606812	606606	606604	606592	606590	606538	606535	606530	606525	606524	606522	606442	606434	Matter No
102487- 014EPDIVPT	102487-037EPFR	102487-037WOCA	102487-037EPGB	102487-036EPAT	102487-021WOCA	102487-021WOMX	102487-021WOCN	102487-020WODE	102487-020WONZ	102487-020WOCA	102487-017WOCA	102487-017WONZ	IP Ref No
ITCA-014/D01PT	ITCA-037/N01FR	ITCA-037/N01CA	ITCA- 037/N01GB	ITCA-036/N01AT	ITCA-021/N01CA	ITCA- 021/N01MX	ITCA- 021/N01CN	ITCA-020/N01EP	ITCA-020/N01NZ	ITCA-020/N01CA	ITCA-017/N01CA	ITCA-017/N01NZ	Client Ref No
Non-Aqueous Single Phase Biocompatible Viscous Vehicles And Methods For Preparing The Same	Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Minimally Compliant, Volume Efficient Piston For Osmotic Drug Delivery Systems	Osmotic Delivery System With Early Zero Order Push Power Engine Comprising An Osmotic Agent Dispersed In The Fluid Vehicle	Osmotic Delivery System With Early Zero Order Push Power Engine Comprising An Osmotic Agent Dispersed In The Fluid Vehicle	Osmotic Delivery System With Early Zero Order Push Power Engine Comprising An Osmotic Agent Dispersed In The Fluid Vehicle	Osmotic Implant With Membrane And Membrane Retention Means	Osmotic Implant With Membrane And Membrane Retention Means	Title/Mark
France	Canada	Great Britain	Austria	Canada	Mexico	China P.R.	Germany	New Zealand	Canada	Canada	New Zealand	Israel	Country
06075430.6	09710406.1	2726861	09710406.1	08743213.4	2490544	PA/a/2005/000224	03818515.6	03760392.5	537136	2489325	2451327	530260	Application No
2/27/2006	2/12/2009	2/12/2009	2/12/2009	4/22/2008	6/25/2003	6/25/2003	6/25/2003	6/17/2003	6/17/2003	6/17/2003	6/21/2002	6/21/2002	Application Date
7/29/2010	12/3/2010	7/29/2010	10/12/2009	12/22/2004			1/6/2005	10/10/2004	12/14/2004	12/19/2003	12/19/2003	5/1/2003	National Filing Date
1666026	2240155	2726861	2240155	2157967	2490544	251860	ZL03818515.6	60315474.3	537136	2489325	2451327	530260	Patent No
12/21/2011	6/6/2012	5/27/2014	6/6/2012	1/16/2013	4/19/2011	11/26/2007	1/21/2009	8/8/2007	11/8/2007	8/10/2010	9/14/2010	3/15/2007	Grant Date
													Publication No
6/7/2006	10/20/2010		10/20/2010	3/3/2010	1/8/2004	6/3/2005	9/21/2005					2/1/2008	Publication Date
Abandoned				Closed									Status

613841	613424	611557	607708	607706	607703	607570	607454	607273	607007	607005	606926	606916	Matter No
102487-052BR	102487- 035WOEPDIV3HK	102487-045-2	102487-043WO	102487-043-1	102487-043-2	102487-010EPGB	102487- 039WOEPDIVHK	102487- 036WOJPDIV3	102487-039CON	102487-036CON	102487- 038WOJPDIV	102487-042-1	IP Ref No
ITCA-052/N01BR				ITCA-043/P01US	ITCA-043/P02US	ITCA- 010/N01GB	ITCA-039/D01HK	ITCA-036/D03JP	ITCA-039/C01US	ITCA-036/C01US	ITCA-038/D01JP	ITCA-042/P01US	Client Ref No
Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist and Co-Administration of a Drug	Osmotic Delivery Systems And Piston Assemblies	High Concentration Formulations, Devices Comprising The Same, And Methods Of Use	Subcutaneous Implant Placement Systems	Subcutaneous Implant Placement Systems	Subcutaneous Implant Placement System	Implanter Device For Subcutaneous Implants	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Osmotic Delivery Device Comprising An Insulinotropic Peptide And Uses Thereof	Highly Concentrated Drug Particles, Formulations, Suspensions And Uses Thereof	Therapeutic Methods For The Treatment Of Diabetes And Related Conditions For Patients With High Baseline HbA1c	Title/Mark
Hong Kong	United States	Patent Cooperation Treaty	United States	United States	Great Britain	Hong Kong	Japan	United States	United States	Japan	United States	Portugal	Country
Not yet filed	19125595.9	62/835,006	PCT/US16/35602	62/170,561	62/170,994	98963214.6	18115056.9	2018-193825	13/645,422	14/605,348	2014-221571	62/057,892	Application No
	8/8/2007	4/17/2019	6/2/2016	6/3/2015	6/4/2015	12/15/1998	9/21/2010	10/12/2018	10/4/2012	1/26/2015	10/30/2014	9/30/2014	Application Date
6/20/2019					6/29/2000	11/23/2018	10/15/2009					9/7/2001	National Filing Date
						1044032							Patent No
						4/21/2004							Grant Date
													Publication No
	3/20/2020		12/8/2016				9/13/2019	3/28/2019	1/31/2013	9/17/2015	1/29/2015		Publication Date
Abandoned	Abandoned		Converted	Converted	Converted	Expired	Published	Published	Abandoned	Abandoned	Abandoned PATI	Expired	Status

PATENT

703798	700024	619602	619185	617295	616782	616394	616166	615946	614179	613847	613846	613845	Matter No
102487-057-1	102487-042CON2	102487- 048WOSGDV	102487-035CON4	102487-028CON5	102487-055PC	102487- 039WOINDIV	102487-037CON4	102487-056-1	102487-052-1	102487-052ZA	102487-052RU	102487-052SG	IP Ref No
ITCA-057/P01US	ITCA-042/C02US		ITCA-035/C04US		ITCA- 055/N01WO		ITCA-037/C03US	ITCA-056/P01US	ITCA-052/P01US				Client Ref No
High Concentration Formulations, Devices Comprising The Same, And Methods Of Use	Therapeutic Methods For The Treatment Of Diabetes And Related Conditions For Patients With High Baseline HbA1c	Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof	Osmotic Delivery Systems And Piston Assemblies For Use Therein	Methods Of Manufacturing Viscous Liquid Pharmaceutical Formulations	Human Amylin Analog Polypeptides And Methods Of Use	Rapid Establishment And/Or Termination Of Substantial Steady-State Drug Delivery	Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents	Long Acting Glucagon Like Polypeptides-1 (GLP-1) Receptor Agonists and Methods of use	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist And Co-administration Of A Drug	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist and Co-Administration of a Drug	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist and Co-Administration of a Drug	Methods Comprising Continuous Administration Of A GLP-1 Receptor Agonist and Co-Administration of a Drug	Title/Mark
United States	Singapore	United States	United States	Patent Cooperation Treaty	India	United States	United States	United States	South Africa	Russian Federation	Singapore	Brazil	Country
62/986.367	16/750,432	10201913699Q	16/702,304	16/709,406	PCT/US19/55696	201918036009	16/551,152	62/952,741	62/441,833	Not yet filed	Not yet filed	Not yet filed	Application No
3/6/2020	1/23/2020	12/30/2019	12/3/2019	12/10/2019	10/10/2019	9/6/2019	8/26/2019	12/23/2019	1/3/2017				Application Date
	11/13/2018				3/26/2012								National Filing Date
													Patent No
													Grant Date
													Publication No
					4/16/2020	11/8/2019							Publication Date
			Abandoned	Abandoned	Published	Published	Abandoned		Expired	Abandoned	Abandoned PAT	Abandoned	Status

708723	707917	705512	712871	705165	705158	705157	Matter No
102487-042CON3	102487- 036WOJPDIV4	102487-058-2	102487-056-1b	102487-060-1	102487-058-1	102487-059-1	IP Ref No
Please Provide	Please Advise	ITCA-058/P02US	ITCA-056/P02US	ITCA-060/P01US	ITCA-058/P01US	ITCA-059/P01US	Client Ref No
Therapeutic Methods For The Treatment Of Diabetes And Related Conditions For Patients With High Baseline HbA1c	Suspension Formulations Of Insulinotropic Peptides And Uses Thereof	Long Acting Peptide Tyrosine Tyrosine (PYY) Analogs And Methods Of Use	Long Acting Glucagon Like Polypeptide -1 (GLP-1) Receptor Agonists and Methods of Use	Use of Human Amylin Analog Polypeptides For Providing Superior Glycemic Control to Type 1 Diabetics	Long Acting Peptide Tyrosine Tyrosine (PYY) Analogs And Methods Of Use	Long Acting Glucagon Receptor Selective Peptides And Methods Of Use	Title/Mark
Japan	United States	United States	United States	United States	United States	United States	Country
16/984,435	2020-000461	63/076,459	63/126,736	63/012,619	63/011,649	63/011,641	Application No
8/4/2020	1/6/2020	9/10/2020	12/17/2020	4/20/2020	4/17/2020	4/17/2020	Application Date
10/15/2009							National Filing Date
							Patent No
							Grant Date
							Publication No
	6/18/2020						Publication Date
	Published						Status

## **GENERAL ASSIGNMENT**

This General Assignment is made as of the 23rd day of December, 2020, by Intarcia Therapeutics, Inc., Inc., a Delaware corporation, with offices at 24650 Industrial Blvd., Hayward, CA 94545 hereinafter referred to as "Assignor", to Intarcia (assignment for the benefit of creditors), LLC, a California limited liability company, hereinafter referred to, along with any successors and assigns, as "Assignee".

## **RECITALS**

WHEREAS, Assignor has determined that, based upon its business prospects, entering into this Assignment is in the best interests of the Assignor's creditors; and

WHEREAS, Assignor believes that Assignee is well qualified to efficiently administer the Assignment for the benefit of the Assignor's creditors;

NOW, THEREFORE, for valuable consideration, the receipt of which is duly acknowledged, the parties agree as follows:

## **AGREEMENT**

## 1. Assignment of Assets.

- (a) Assignor, for and in consideration of the covenants and agreements to be performed by Assignee, as hereinafter contained, and for good and valuable consideration, receipt whereof is hereby acknowledged, does hereby grant, bargain, sell, assign, convey and transfer to Assignee, its successors and assigns, in trust, for the benefit of Assignor's creditors generally, all of the property of Assignor of every kind and nature and wheresoever situated, both real (but not facility lease arrangements) and personal, and any interest or equity therein not exempt from execution, including, but not limited to, all that certain stock of merchandise, equipment, furniture, fixtures, accounts, books, cash on hand, cash in bank, deposits, patents, copyrights, trademarks and trade names and all associated goodwill, source codes, software, and related documentation, insurance policies, and choses in action that are legally assignable, together with the proceeds of any existing non-assignable choses in action that may hereafter be recovered or received by Assignor. Assignor agrees to execute such additional documents as shall be necessary to accomplish the purposes of this Assignment.
- (b) This Assignment specifically includes and covers all claims for refund or abatement of all excess taxes heretofore or hereafter assessed against or collected from Assignor by the U.S. Treasury Department or any other taxing agency, and Assignor agrees to sign and execute power of attorney or such other documents as required to enable Assignee to file and prosecute, compromise and/or settle, all such claims before the Internal Revenue Service, U.S. Treasury Department or any other taxing or other Governmental agency.

- (c) Assignee is to receive said property, conduct said business, should it deem it proper, and is hereby authorized at any time after the signing hereof by Assignor to sell and dispose of said property upon such time and terms as it may see fit, and is to pay to creditors of Assignor pro rata, the net proceeds arising from the conducting of said business and sale and disposal of said property, after deducting all moneys which Assignee may at its option pay for the discharge of any lien on any of said property and any indebtedness which under the law is entitled to priority of payment, and all expenses, including a reasonable fee to Assignee and its attorneys.
- 2. <u>Payment of Fees</u>. Assignee shall be entitled to pay the fees and expense reimbursements set forth in the Compensation and Expense Reimbursement Agreement dated as of the date hereof between the Assignor and the Assignee (the "Fee Letter").
- 3. Appointment of Agents. Assignee is authorized and empowered to appoint and compensate such agents, field representatives and/or attorneys and/or accountants as it may deem necessary, and such agents and/or field representatives shall have full power and authority to open bank accounts in the name of Assignee or its nominees or agents and to deposit assigned assets or the proceeds thereof in such bank accounts and to draw checks thereon and with the further power and authority to do such other acts and to execute such papers and documents in connection with this Assignment as Assignee may consider necessary or advisable.
- Certain Acknowledgments Regarding Transfer. Assignor acknowledges that certain of the assets being assigned under this General Assignment may be subject to restrictions on the use or transfer of such assets, the unauthorized use or transfer of which may result in further damages or claims. Such assets may include, without limitation, intellectual property rights of the Assignor (e.g., trade names, service names, registered and unregistered trademarks and service marks and logos; internet domain names; patents, patent rights and applications therefor, copyrights and registrations and applications therefor; software and source code (and software licenses with respect thereto); customer lists and customer information; know-how, trade secrets, inventions, discoveries, concepts, ideas, methods, processes, designs, formulae, technical data, drawings, specifications, data bases and other proprietary assets (collectively, "Intellectual Property")). Assignor represents and warrants that its officers, directors, shareholders, employees, agents, customers and other third parties have been advised not to use, remove or cause a transfer (other than pursuant to this General Assignment) of any of the assets of Assignor, including without limitation the Intellectual Property, either prior or subsequent to this General Assignment, except as expressly authorized in writing in advance, which written authorization is not inconsistent with or otherwise may constitute a breach of any other written agreement. Except as authorized in writing, which has been disclosed in writing to Assignee, Assignor further represents and warrants that no asset (including, without limitation, the Intellectual Property) has been transferred, used, or removed, in whole or in part, in a manner that interferes with the rights and interests of a third party(ies) in such asset or otherwise may constitute a breach of any contract with such third party(ies).

- 5. Representations and Warranties of the Assignor. Assignor represents and warrants to Assignee that as of the date hereof:
- (a) Assignor has all requisite power and authority to execute, deliver and perform its obligations under this Assignment, including, without limitation, to transfer the property transferred to the Assignee hereby;
- (b) the execution, delivery and performance by the Assignor of this Assignment has been duly authorized by all necessary corporate and other action and does not and will not require any registration with, consent or approval of, or notice to or action by, any person (including any governmental authority) in order to be effective and enforceable;
- (c) this Assignment constitutes the legal, valid and binding obligation of the Assignor, enforceable against it in accordance with their respective terms; and
- (d) all claims for wages, expense reimbursements, benefits and other compensation with priority over the Assignor's other creditors pursuant to California Code of Civil Procedure § 1204 accrued or otherwise arising prior to the date hereof have been satisfied in full.
- 6. Resignation and Replacement of Assignee. The Assignee may resign and, as a result of such resignation, be discharged from its duties hereunder at any time; provided that such resignation shall not become effective until a successor Assignee has been appointed by the resigning Assignee and such successor has accepted its appointment in writing delivered to the resigning Assignee. Any successor Assignee appointed hereunder shall execute an instrument accepting such appointment hereunder and shall deliver one counterpart thereof to the resigning Assignee. Thereupon such successor Assignee shall, without any further act, become vested with all the estate, properties, rights, powers, trusts, and duties of his predecessor in connection with the Assignment with like effect as if originally named therein, but the resigning Assignee shall nevertheless, when requested in writing by the successor Assignee, execute and deliver an instrument or instruments conveying and transferring to such successor Assignee all of the estates, properties, rights, powers and trusts of such resigning Assignor in connection with the Assignment, and shall duly assign, transfer, and deliver to such successor Assignee all property and money held by it hereunder.
- 7. <u>Limitation of Liability</u>. Assignor acknowledges that Assignee is acting solely as Assignee in connection with this Assignment and not in its personal capacity. As a result, Assignor expressly agrees that Assignee, its members, officers and agents shall not be subject to any personal liability whatsoever to any person in connection with the affairs of this Assignment, except for its own misconduct knowingly and intentionally committed in bad faith. No provision of this Agreement shall be construed to relieve the Assignee from liability for its own misconduct knowingly and intentionally committed in bad faith, except that:

- (a) The Assignee shall not be required to perform any duties or obligations except for the performance of such duties and obligations as are specifically set forth in this Assignment, and no implied covenants or obligations shall be read into this Assignment against the Assignee.
- (b) In the absence of bad faith on the part of the Assignee, the Assignee may conclusively rely, as to the truth, accuracy and completeness thereof, on the statements and certificates or opinions furnished to the Assignee by the Assignor and conforming to the requirements of this Assignment.
- (c) The Assignee shall not be liable for any error of judgment made in good faith.
- (d) The Assignee shall not be liable with respect to any action taken or omitted to be taken by it in accordance with a written opinion of legal counsel addressed to the Assignee.

In connection with the foregoing, the assignment estate shall defend, indemnify and hold the Assignee and its past and present officers, members, managers, directors, employees, counsel, agents, attorneys, parent, subsidiaries, affiliates, successors and assigns, including without limitation Sherwood Partners, Inc. (collectively, the "Indemnified Persons") harmless from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, charges, expenses and disbursements (including reasonable attorneys' fees and costs) of any kind or nature whatsoever which may at any time be imposed on, incurred by, or asserted against any such Indemnified Person in any way relating to or arising out of this General Assignment, the Fee Letter, any other document contemplated by or referred to herein or therein, the transactions contemplated hereby or thereby, or any action taken or omitted by any Indemnified Person under or in connection with any of the foregoing, including, without limitation, with respect to any investigation, litigation or proceeding related to or arising out of any of the foregoing, whether or not any Indemnified Person is a party thereto, and including, without limitation, any other Indemnified Claims (defined below), provided, that the assignment estate shall have no obligation hereunder to any Indemnified Person with respect to indemnified claims to the extent resulting from the willful misconduct or gross negligence of any Indemnified Person. The foregoing indemnification shall survive any termination of this General Assignment or the transactions contemplated hereby. For purposes hereof, "Indemnified Claims" means any and all claims, demands, actions, causes of action. judgments, obligations, liabilities, losses, damages and consequential damages, penalties, fines, costs, fees, expenses and disbursements (including without limitation, fees and expenses of attorneys and other professional consultants and experts in connection with investigation or defense) of every kind, known or unknown, existing or hereafter arising, foreseeable or unforeseeable, which may be imposed upon, threatened or asserted against, or incurred or paid by, any Indemnified Person at any time and from time to time, because of, resulting from, in connection with, or arising out of any transaction, act, omission, event or circumstance in any way connected with this General Assignment, the Fee Letter, any other document contemplated by or referred to

herein or therein, the transactions contemplated hereby or thereby, or any action taken or omitted by any Indemnified Person under or in connection with any of the foregoing, including but not limited to economic loss, property damage, personal injury or death in connection with, or occurring on or in the vicinity of, any assets of the assignment estate through any cause whatsoever, any act performed or omitted to be performed under this General Assignment, any other document contemplated by or referred to herein, the transactions contemplated hereby, or any action taken or omitted by any Indemnified Person under or in connection with any of the foregoing, any breach by Assignor of any representation, warranty, covenant, agreement or condition contained herein or in any other agreement between Assignor and Assignee.

Power of Attorney. Assignor, by this General Assignment, hereby grants Assignee, an irrevocable general power of attorney, coupled with an interest, which power of attorney is for all purposes and specifically includes the right of Assignee (i) to prosecute any action in the name of Assignor as Attorney in Fact, including, but not limited to, the claims or actions identified on Schedule "A" hereto, and (ii) to transfer or assign patents, patent applications and other intellectual property, and any other assets, by the execution of assignment agreements and, where appropriate, through filings with the U.S. patent and trademark office and other U.S. and foreign filing offices. Further, on the date this General Assignment is accepted by Assignee, Assignee shall succeed to all of the rights and privileges of Assignor, including any attorney-client privilege in respect to any potential or actual claims, cases, controversies, causes of action, etc. (including, but not limited to, the claims or actions identified on Schedule "A" hereto) and shall be deemed to be a representative of Assignor with respect to all such potential or actual claims, cases, controversies, and causes of action (including, but not limited to, the claims or actions identified on Schedule "A" hereto). While Assignee is not required to defend any action being asserted against Assignor, Assignor, by this General Assignment, hereby grants Assignee an irrevocable general power of attorney, coupled with an interest, which power of attorney specifically includes the right, but not the obligation, of Assignee to defend against any action pending or brought against Assignor in the name of Assignor as Attorney in Fact.

## 9. Reliance.

- (a) The Assignee may rely and shall be protected in acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, or other paper or document believed by it to be genuine and to have been signed or presented by the proper party or parties.
- (b) The Assignee may consult with legal counsel to be selected by it, and the Assignee shall not be liable for any action taken or suffered by it in accordance with the advice of such counsel.
- (c) Persons dealing with the Assignee shall look only to the assignment estate to satisfy any liability incurred by the Assignee in good faith to any such person in carrying out the terms of this Assignment, and the Assignee shall have no personal or individual obligation to satisfy any such liability.

PATENT REEL: 065114 FRAME: 0536

5

- 10. <u>Headings</u>. The headings used in this Assignment are for convenience only and shall be disregarded in interpreting the substantive provisions of this Assignment.
- 11. <u>Forwarding of Mail</u>. Assignor authorizes the forwarding of its mail by the U.S. Postal Service as directed by Assignee.
- 12. <u>Counterparts</u>. This Assignment agreement may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same document. Facsimile or electronically transmitted signatures shall have the same force and effect as original signatures.
- 13. <u>Attorneys fees and costs</u>. Except as set forth in the Fee Letter, the parties agree that each of them shall bear its own legal costs and expenses in connection with the negotiation, drafting, execution or enforcement of this Assignment.
- 14. <u>Entire Agreement</u>. This Assignment and the Fee Letter contain the entire agreement of the parties hereto with respect to the matters covered and the transactions contemplated hereby, and no other agreement, statement, representation, warranty or promise made prior hereto or contemporaneously herewith by any party hereto, or any employee, officer, agent, or attorney of any party hereto shall be valid or binding or relied upon by any party as an inducement to enter into, or as consideration for, this Assignment.
- 15. Governing Law. This General Assignment shall be governed by and construed in accordance with the laws of the State of California without regard to conflicts of law principles.
- 16. Severability. In case any provision of this General Assignment shall be invalid, illegal or unenforceable, such provision shall be severable from the remainder of this General Assignment and the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.
- 17. Cooperation. Each party cooperated in the drafting of this General Assignment and therefore this General Assignment shall not be construed more strictly against any of the parties.
- 18. Time is of the Essence. Time is of the essence in the performance of and conditions set forth in this General Assignment.
- 19. No Adequate Remedy at Law. Each party hereto acknowledges and agrees that damages will not adequately compensate the other party for a breach of the terms of this General Assignment and that, as such, each party shall be entitled to specific performance of this General Assignment.

Assignor's Federal Tax I.D. Number:

Federal # 68-0364181

By: Kurt Graves
Chairman, President & CEO

Intarcia (assignment for the benefit of creditors), LLC, a California limited liability company, Assignee

By: Its: with

Manager

IN WITNESS WHEREOF the parties hereunder set their hands the day and year

first above written.

# Schedule A

- None



TITLE Intarcia General Assignment

FILE NAME Intarcia Therapeu...al Assignment.pdf

**DOCUMENT ID** ef755f5c3577eaa5ae6b5c57f9396b43800a476d

AUDIT TRAIL DATE FORMAT MM / DD / YYYY

**STATUS** & Completed

**Document History** 

Sent for signature to Michael A. Maidy (mam@shrwood.com)

03:38:58 UTC from ckarma@shrwood.com

IP: 12.53.4.238


Viewed by Michael A. Maidy (mam@shrwood.com)

VIEWED 05:04:10 UTC IP: 73.189.4.43

\$\frac{12}{31} / 2020 \quad \text{Signed by Michael A. Maidy (mam@shrwood.com)}

The document has been completed.

COMPLETED 05:04:25 UTC



**RECORDED: 10/03/2023**